Review

Novel Pharmacological Approaches to the Treatment of Depression

Elias Elias †, Ariel Y. Zhang †✉ and Melissa T. Manners *✉

Department of Biological Sciences, University of the Sciences, 600 South 43rd Street, Philadelphia, PA 19104, USA; eelias@mail.usciences.edu (E.E.); azhang0109@mail.usciences.edu (A.Y.Z.)
* Correspondence: mmanners@usciences.edu
† These authors contributed equally to this work.

Abstract: Major depressive disorder is one of the most prevalent mental health disorders. Monoamine-based antidepressants were the first drugs developed to treat major depressive disorder. More recently, ketamine and other analogues were introduced as fast-acting antidepressants. Unfortunately, currently available therapeutics are inadequate; lack of efficacy, adverse effects, and risks leave patients with limited treatment options. Efforts are now focused on understanding the etiology of depression and identifying novel targets for pharmacological treatment. In this review, we discuss promising novel pharmacological targets for the treatment of major depressive disorder. Targeting receptors including N-methyl-D-aspartate receptors, peroxisome proliferator-activated receptors, G-protein-coupled receptor 39, metabotropic glutamate receptors, galanin and opioid receptors has potential antidepressant effects. Compounds targeting biological processes: inflammation, the hypothalamic-pituitary-adrenal axis, the cholesterol biosynthesis pathway, and gut microbiota have also shown therapeutic potential. Additionally, natural products including plants, herbs, and fatty acids improved depressive symptoms and behaviors. In this review, a brief history of clinically available antidepressants will be provided, with a primary focus on novel pharmaceutical approaches with promising antidepressant effects in preclinical and clinical studies.

Keywords: antidepressant; natural products; major depressive disorder; pharmacological treatment; mental health; monoamine deficiency; opioid receptors; NMDAR; PPAR; mGluR; inflammation; HPA axis; microbiome; fatty acids

1. Introduction

Major depressive disorder (MDD) is one of the leading mental health conditions in the world. According to the World Health Organization, more than 264 million people are diagnosed with MDD worldwide [1]. MDD is a heterogeneous disease and is defined as a 2-week period during which a person experiences any combination of daily depressive symptoms including altered occupational and social functioning, altered mood, impaired daily activities and habits, loss of energy and interest in pleasurable tasks, weight changes, or sleep disturbances [2]. Most patients diagnosed with MDD report recurring depressive episodes [3], inducing suffering and increasing the risk of suicidality and death [4].

The development of the first antidepressant drugs in the 1960s was fueled by the monoamine deficiency hypothesis that monoamine neurotransmitter deficiency is the leading cause of MDD. This led to the development of the first generation of antidepressant monoamine oxidase inhibitors (MAOIs) and then tricyclic antidepressant agents (TCAs). Soon after, the role of serotonin in MDD was identified [5] and led to the development of current first-line therapeutics, selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine reuptake inhibitors (SNRIs). There are notable shortcomings with classic antidepressants, including adverse events and delayed onset of efficacy [6]. Notably, over a third of patients do not respond to classic antidepressant treatment, which classifies...
these patients with treatment-resistant depression (TRD) [7]. More recently, the discovery of ketamine as an efficacious antidepressant led to the approval of a nasal spray form of esketamine [8]. Esketamine provides fast-acting symptomatic relief in TRD patients, yet the significant risks associated with esketamine limit its use for a broad patient population. Together, the adverse events, low efficacy, and dosing risks of currently approved medications leave MDD patients with inadequate treatment options. There are considerable challenges in treating patients with MDD due to the unique combination of symptoms each patient experiences. The etiological complexity of MDD indicates that this disorder is not a unitary disease. There are distinct pathophysiological mechanisms underlying susceptibility and resilience to the development of depression [9,10]. The majority of current antidepressants target monoamines, yet the limited responsiveness of MDD patients to these pharmacological treatments implicates that additional underlying mechanisms need to be considered in order to improve the efficacy of treatments [11]. Thus, expanding the currently available treatment options will work toward the goal of personalizing the pharmacological treatment plan of individual patients based on the specific considerations of their diagnosis.

In this review, we compiled the most up-to-date research on natural products, biological processes, and receptors that could serve as important novel targets to improve the outcomes of MDD treatment. Avenues to improve treatment options for patients include exploring novel targets, determining additional mechanisms of action of current antidepressants, or evaluating synergistic compounds for treatment. Therefore, the aim of this review is to provide a brief overview of currently available antidepressants and a detailed review of new molecular targets with promising potential for the treatment of MDD. In doing so, we suggest novel approaches that should be further explored for personalized antidepressant development.

2. Materials and Methods

The systemic literature search for this review was conducted in PubMed. The search was limited to publications written in English and publications assigned a PMID. Articles were chosen based on their relevance to the three major sections of this review, pharmacological agents targeting receptors or biological processes, or natural products with antidepressant potential.

3. Clinically Available Antidepressants

In this section, antidepressants that are currently available to patients are reviewed chronologically from when they were developed. Although these antidepressants are critical tools for the treatment of MDD patients, there are numerous limitations to their use: adverse effects, administration risks, delayed onset of antidepressant therapy, or limited efficacy. Therefore, in this section, we briefly review the efficacy of these drugs, potential off-label uses, and limitations for the treatment of MDD.

3.1. Monoamine Oxidase Inhibitors

MAOIs increase serotonin (5-HT or 5-hydroxytryptamine), norepinephrine and dopamine concentration in the synapse by inhibiting breakdown by monoamine oxidase A (MAO-A) and B (MAO-B). Iproniazid was the first MAOI used for the treatment of depression [12]. It was originally designed to treat tuberculosis; however, improved mood, stimulation of the central nervous system (CNS) and increase in 5-HT were also observed [13]. Iproniazid showed a 25% to 75% recovery rate in MDD patients and alleviated symptoms of atypical depression [14]. However, non-selective and irreversible binding resulted in a high concentration of tyramine, hypotension, and liver damage [15]. To improve MAOIs safety and efficacy, selective and reversible inhibitors of monoamine oxidase A (RIMA) were introduced in the 1980s. Moclobemide is a RIMA that has been widely used in MDD treatment [16].
Phenelzine, tranylcypromine, and isocarboxazid are also first generation MAOIs that are still used for TRD [17] in combination with other antidepressants [18,19]. Patients taking these drugs are required to limit tyramine intake to reduce the risk of developing hypertension [20].

Recent studies have focused on the off-label use of MAOIs for the treatment of Parkinson’s disease. These studies revealed that in animal models, selegiline and rasagiline improved synaptic plasticity by restoring long-term potentiation [21], and decreased cortical dopamine turnover time [22]. Improved motor function was observed in patients, indicating a promising therapeutic effect [23].

3.2. Tricyclic Antidepressants

Similar to MAOIs, TCAs also target the breakdown of monoamine neurotransmitters [17]. To enhance 5-HT and norepinephrine transporter (NET) function, TCAs desensitize 5-HT and NET presynaptic receptors by inhibiting the reuptake transporters and causing the accumulation of 5-HT and NET in the presynaptic cleft. In the absence of transport protein and postsynaptic breakdown, 5-HT and NET concentrations in the synaptic cleft increase, which is the presumed mechanism for improving mood to alleviate MDD symptoms [24]. Additionally, TCAs act as competitive antagonists on postsynaptic histamine, adrenergic and muscarinic receptors [17,18], which leads to various side effects of TCAs [25].

Imipramine, clomipramine (CLO), and doxepin (DXP) were among the first generation of TCAs produced [19,26]. Although these drugs have a common mechanism of action, there are advantages to each depending on the patient’s symptoms. CLO has a higher efficacy in treating MDD compared to imipramine [27]. DXP improves sleep in MDD patients [28,29] and is approved by the Food and Drug Administration (FDA) for insomnia treatment [30]. Nortriptyline is often prescribed to MDD patients with ischemic heart disease [31] as it reduces platelet activation [32].

Unfortunately, TCAs can have serious adverse effects. Antagonism of the postsynaptic histamine, adrenergic and muscarinic receptors, caused different levels of adverse effects such as drowsiness [33], pregnancy complications [34], and cardiac abnormalities such as abnormal cardiac conduction, arrhythmia, and myocardial infarction [35,36]. In utero exposure to CLO caused withdrawal symptoms including convulsion, increased heart rate, and cyanosis within 24 h post-partum [37]. More efficacious treatments such as SSRIs or SNRIs are available and therefore, TCAs are no longer the first choice for antidepressant treatment [38].

Research on the use of TCAs for chronic migraine [39], insomnia [40,41], alcohol use disorder [42,43], and neuropathic corneal pain has been conducted with indications of therapeutic efficacy, though adverse effects remain a concern.

3.3. Selective Serotonin Reuptake Inhibitors

In the 1960s, researchers uncovered the potential role of serotonin in MDD [5]. One of the suggested therapeutic approaches was the inhibition of serotonin reuptake to enhance stimulation of postsynaptic serotonin receptors, which led to the development of SSRIs. Fluoxetine was the first SSRI to be FDA approved, followed by numerous SSRIs with reduced adverse effects. Although SSRIs produce an increase in serotonin in the synapse, there is a delayed onset of efficacy, which can be 2–3 weeks in duration [6]. Investigation into the mechanism of antidepressant action expanded from increasing serotonin in the synapse to increasing hippocampal neurogenesis [44–46].

Because of the high tolerance and broad-spectrum efficacy, SSRIs are prescribed as a first-line medication for depressed patients of different ages. However, patients reported adverse events including headache, agitation, nausea, diarrhea, insomnia [47], sexual dysfunction [48], gynecomastia [49], weight gain, and gastrointestinal distress [50].

The primary goal of current research is to identify key factors needed to minimize adverse effects and delayed onset of therapeutic action. SSRI-induced upregulation of the brain-derived neurotrophic factor (BDNF) [51] and dopamine receptor D1 [52], reduction
of inflammatory factors involved in the c-jun N-terminal kinase 1/2 and the extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) pathways [53,54], or phosphorylation of the mammalian target of rapamycin (mTOR) [55] could be involved in the antidepressant action of SSRI. The unique molecular mechanisms underlying the activity of SSRIs may be an important consideration for determining the cause of adverse effects and delayed onset of efficacy, and could lead to the development of improved therapeutics.

3.4. Serotonin-Norepinephrine Reuptake Inhibitors

SNRIs inhibit the reuptake of two important neurotransmitters involved in depression: serotonin and norepinephrine. The first developed SNRI, venlafaxine, was FDA approved and marketed in the United States of America (USA) in 1993 as a first-line treatment for depression [56]. Over the following decade, desvenlafaxine [57], duloxetine [58], levomilnacipran [59], milnacipran [60], and other SNRIs were also approved. Treatment of depressed adult patients with levomilnacipran increased thickness in the left insular cortex [61]. This link between levomilnacipran and cortical thickness has been studied in previous clinical trials, but the underlying mechanism of action has not been elucidated.

Duloxetine is an SNRI with the potential to treat neuropathic pain. Duloxetine decreased chemotherapy-induced nerve pain by inhibiting p53 [62], p38 phosphorylation, and NF-κB activation [63]. Because chronic pain and depressive disorders are frequent comorbidities, clinical trials should explore the potential of SNRIs to treat neuropathic pain conditions while preventing depressive symptoms in these patients.

Side effects of SNRIs are similar to SSRIs, including tiredness, constipation, insomnia [64], and potentially the dysregulation of some metabolic processes associated with hyperglycemia [65,66]. Despite the observed success in treating MDD patients, first-line therapeutics are not effective in many patients, resulting in multiple adverse effects and delayed efficacy [67]. This shifted the therapeutic need to drugs that are fast-acting, with reduced adverse effects and improved efficacy for TRD.

3.5. Ketamine

Ketamine, a phencyclidine derivative, is a noncompetitive N-methyl-D-aspartate receptor (NMDAR) antagonist developed as an anesthetic in the 1960s. NMDARs are heteromeric ionotropic glutamatergic receptors that are activated by the binding of both glycine and glutamate to their corresponding binding site (NR1 and NR2 subunits respectively) and are inhibited by magnesium ions binding to the phencyclidine site. Thus, ketamine antagonistic activity is delivered by binding to the phencyclidine site or by non-selectively binding to the NR2 site (A–D subunits) [68–70].

The first clinical trial that tested the therapeutic potential of ketamine as an antidepressant was conducted in 2000 [71]. Delivering its effects in as little as 30 min for patients with TRD [72–74] or bipolar depression [75], ketamine was considered the first fast-acting antidepressant. Administration of ketamine to patients is problematic and impractical; antidepressant effects are short acting, and the lack of protracted effects require frequent intravenous administration by an anesthesiologist [3].

There are two active enantiomers of ketamine, both with antidepressant activity, R-ketamine (also known as arketamine) and S-ketamine (also known as esketamine). Despite the lower affinity of arketamine to NMDAR, preclinical models identified enhanced protracted antidepressant effects [76–78], which were confirmed in a recent clinical trial [79].

In 2019, a nasal spray form of esketamine was approved by the FDA in the USA and Europe [80]. MDD and TRD patients who received esketamine alone or in combination with standard antidepressants had significant improvement in MDD symptoms compared to standard antidepressants [80], with high tolerability and safety [81]. Additionally, this enantiomer is used for patients with severe illness or active suicidal thoughts [82].

There are continuing safety concerns that restrict the usage of esketamine due to multiple adverse events including hyperhidrosis, dissociation, urinary pain, and suicidal ideation [83–85]. Therefore, extensive research is being conducted to study key factors
involved in the mechanism of action, with the goal of developing new and improved therapeutics for MDD treatment that are fast-acting and long-lasting, with reduced adverse effects and abuse liability. Some proposed mechanisms include regulation of the neuropeptide precursor VGF [86], stimulation of serotonin1A receptor [87], activation of the BDNF pathway, induction of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor ( AMPAR) [88], and activation of the ventral CA3 hippocampal regions [89].

3.6. γ-Aminobutyric Acid

γ-Aminobutyric acid (GABA) is a neurotransmitter that activates two classes of receptors: the ionotropic and metabotropic receptors (GABA_A Rs and GABA_B Rs), mediating neural inhibition in the CNS [90,91]. Ionotropic receptors are targeted by allosteric modulators benzodiazepines (Bz) and barbiturates [92] to produce an anxiolytic effect. Metabotropic receptors regulate excitatory postsynaptic potentials and have been considered in affective disorders.

The GABAergic system is dysregulated in depressive patients. GABA synthesizing neurons are decreased in the orbitofrontal cortex of MDD patients [93], cortical GABA is downregulated in postpartum depression [94], and TRD patients have decreased binding of Bz in the frontal and orbitotemporal cortex [95]. Following SSRI treatment, depressive patients have increased cortical GABA [96], and upregulated levels of allopregnanolone and pregnanolone, two GABA-active steroid agonists [97].

GABAergic drugs that are predicted to have antidepressant activity from preclinical studies included valproate [98], amino-oxyacetic acid [99], beta-phenyl-GABA [100], muscimol [101], diazepam [102], carbamazepine, and oxcarbazepine [103].

More evidence for the role of the GABAergic system in depressive disorders is its involvement in the serotonergic system [104] and its contribution to the ketamine response through glutamate synaptic changes or cortical excitatory-inhibitory balance reestablishment [105,106]. GABA_B receptors are important for the antidepressant activity of ketamine [107], and other GABA_B agonists such as baclofen, CGP7930, and SKF97541 showed significant antidepressant activity [108].

One of the remaining challenges is investigating the extent to which the GABAergic system dysregulation or imbalance impacts specific subsets of MDD patients. Given the widespread coverage of GABAergic neurons, their innervation in other modulatory systems, and the strong link between modulating GABA and the efficacy of antidepressants, the GABAergic system remains a critical area of research and could be important in achieving the antidepressant activity of potential future therapeutics.

4. Potential Antidepressants Targeting Receptors

One approach to developing new treatments for MDD is targeting specific receptors and receptor families that are implicated in the pathophysiology of depression. In this section, we review preclinical and clinical reports that target specific classes of receptors for the treatment of depression. Receptor families discussed below have been understudied in the field of depression and demonstrated promising novel treatment options. This section, Supplementary Tables S1 and S2 summarize agonists, antagonists, and other regulators that could lead to promising potential antidepressants.

4.1. Opioid Receptors

The delta (DOR), kappa (KOR), and mu (MOR) opioid receptors are endogenous G protein-coupled receptors. They are expressed throughout the nervous system and regulate important physiological functions such as stress response, reward process, and mood. Opioid receptors are activated via binding of endorphin, enkephalin (ENK), dynorphin, and nociceptin/orphanin FQ, and have numerous downstream effects. Modulating the opioid receptors has antidepressant potential, through specific or non-specific agonists and antagonists.
Buprenorphine (BUP) is a partial MOR agonist and a DOR and KOR antagonist, with a high affinity for MOR and KOR and a lower affinity for DOR [109,110]. It was originally approved as an analgesic to treat moderate to severe pain [111] and withdrawal symptoms from opioid dependence [112]. For the last several decades, it has been administered when patients did not respond to conventional antidepressants [113]. It improved mood, reduced anxiety behavior, and suicidal ideations [114]. It also rapidly improved TRD symptoms within the first three weeks with no serious side effects [115]. Combinatorial treatment of BUP/samidorphan was also efficacious and was well tolerated in depressed patients with no signs of abuse or opioid dependence/withdrawal [116,117]. Similar to BUP, nalmefene targets multiple opioid receptors and was shown to prevent inflammation-induced depressive-like behaviors in rodents and cognitive impairment by decreasing hyperactivity in the hypothalamus-pituitary-adrenal (HPA) axis and increasing BDNF expression [118]. More studies should be conducted to determine if nalmefene has therapeutic potential in humans.

There is also an opportunity to develop therapeutics targeting specific opioid receptors for the treatment of MDD. ENK is a pentapeptide that binds to DOR and MOR, and has been used as an analgesic since the 1970s [119]. Chronic mild stress upregulated ENK production and activated the MOR and DOR signaling pathway, while ENK knockout mice did not express depressive-like or anxiety-like behaviors. This finding suggests that inhibition of ENK promotes stress resilience and that this pathway is a potential therapeutic target for MDD [120]. KNT-127 [121], Rubiscolin-6 [122], and SNC80 [123] are preclinical DOR receptor agonists that decreased depressive-like behaviors in mouse models of depression. N/OFQ is an endogenous opioid peptide that binds to nociceptin receptor (NOPr), part of the opioid receptor family [124]. NOPr antagonists such as LY2940094 [125] and UFP-101 [126] reduced anhedonia and rescued stress-like and anxiety-like behaviors by restoring neurogenesis after chronic stress.

Tianeptine is classified as a μ-opioid receptor agonist that has been shown to have antidepressant effects, with no negative effects on sleep, cognitive function, or memory [127]. In rodents, tianeptine reduced depressive-like behaviors and inflammatory factors in the hippocampus and prefrontal cortex (PFC) [128], reduced avoidant behavior [129], and had positive effects on energy and metabolic processes [130]. A number of studies have reported the enhanced efficacy of tianeptine when combined with another pharmacotherapy. Mice administered tianeptine and cannabinoid targeting drugs had reduced depressive-like behaviors [131]. Ramoz et al. recently reported an association between the antidepressant effects of tianeptine and the corticotropin-releasing hormone receptor in patients experiencing major depressive episodes [132].

It is unknown if tianeptine provides improved antidepressant effects compared to first-line antidepressant treatments. However, the combined clinical and preclinical evidence suggests that further clinical studies should be conducted to ascertain whether tianeptine should be considered for individual or combinatorial treatment for MDD patients.

Opioid receptor-targeting treatments have been effective for patients with TRD [133], which indicates that TRD patients require molecular targets unique from monoamines. Given the involvement of opioid receptors in stress, reward, mood, and biological and cellular processes such as inflammation, it is expected that targeting this family of receptors would be efficacious for treating psychiatric diseases [134–136]. However, targeting the opioid system is problematic as chronic usage has an abuse potential, and the development of tolerance or withdrawal symptoms may occur. Therefore, the major challenges in developing opioid targeting drugs have likely hindered progress in the development of novel therapeutics.

4.2. N-methyl-D-aspartate Receptors

Increased glutamate is also associated with MDD. The binding of glutamate activates NMDAR and mediates cell depolarization. AMPAR is another type of ionotropic and glutamatergic receptor. The density and stability of AMPAR are crucial for synaptic
transmission [137] and can mediate antidepressant effects upon activation [138]. Both preclinical and clinical studies have extensively focused on NMDAR antagonists for the treatment of depression. In this section, we focus on non-ketamine related potential therapeutic targets for the treatment of MDD.

Nitrous oxide (N\textsubscript{2}O) is an NMDAR antagonist that has antidepressant properties similar to ketamine. N\textsubscript{2}O activated neuronal nitric oxide synthase and restored synaptic plasticity [139]. N\textsubscript{2}O exposure reduced depressive-like behaviors, increased BDNF expression, and neuron firing rate in the medial PFC of mice [140]. N\textsubscript{2}O also demonstrated a rapid antidepressant effect in TRD patients with a high treatment response rate [141] and significantly improved Hamilton Depression Rating Scale scores in MDD patients with a high remission rate. Although N\textsubscript{2}O may be promising for TRD treatment, there are obstacles for utilizing this treatment such as side effects [142] and inconvenient administration.

Memantine, another NMDAR antagonist, was effective in treating MDD patients over 60 years old in combination with standard SSRI treatment. Importantly, no major side effects were reported [143], indicating that memantine is a potential therapeutic agent for combinatorial therapy with SSRI in aging adults with MDD. Further investigation to determine if effects are age-specific is needed to evaluate the potential limitations of this treatment. Riluzole inhibited post-synaptic glutamic release by noncompetitive blockade of NMDAR and exhibited a rapid antidepressant effect in patients with moderate to severe MDD [144].

A number of other NMDAR antagonists has promising behavioral effects in rodents. Amantadine, which is used as an antiviral, is an NMDAR antagonist that was shown to have antidepressant and anti-inflammatory effects [145]. Lanicemine and MK-801 are NMDAR antagonists that rapidly rescued stress-induced depressive-like behaviors [146–148]. Ro 25-6981, a selective NMDAR inhibitor with high oral permeability, reduced depressive-like symptoms in rodents, indicating the potential to develop orally administered NMDAR antagonists [149].

The GluN2B subunit is one of the major components in NMDAR and plays functional roles in NMDA signaling [150]. Blockage of GluN2B and inhibition of GluN2B phosphorylation exerted rapid antidepressant-like effects in animal models [151,152]. Pharmacological studies are being conducted to determine the mechanism of action of the GluN2B subunit. Ifenprodil, a GluN2B selective antagonist, reduced depressive-like behaviors through mTOR activation [153]. Rislenemdaz decreased GluN2B activity and BDNF expression in the lateral habenula [154]. An NMDAR positive allosteric modulator, AGN-241751, rapidly promoted antidepressant behavior by enhancing GluN2B-NMDA signaling and increasing the concentration of synaptic protein in the medial PFC [155]. Traxoprodil, a GluN2B antagonist, reduced depressive-like behaviors and reinforced the antidepressant effect elicited by conventional MDD treatments such as desipramine, paroxetine, milnacipran, and bupropion [156,157].

NMDAR antagonists have delivered rapid antidepressant effects in pre-clinical models and clinical evidence confirms these effects, though more clinical trials are necessary to verify efficacy. Specifically targeting the GluN2B subunit of NMDAR is a novel approach for delivering fast-acting symptom reduction and could be utilized as an alternative to ketamine-derived drugs for patients with suicidal ideation. Further exploration on combinatorial therapy of NMDAR antagonists with SSRI or SNRI could provide fast-acting symptom relief from the NMDAR antagonist and sustained antidepressant activity from SSRI or SNRI. Other NMDAR antagonists such as memantine and amantadine require rigorous clinical trials to determine if they can be used to treat TRD.

4.3. Peroxisome Proliferator-Activated Receptors

The peroxisome proliferator-activated receptors (PPARs) are transcription factors that play a role in lipid metabolism, glucose regulation, energy homeostasis, and inflammation. Decreased levels of the PPAR subtypes (\(\alpha\), \(\beta/\delta\), and \(\gamma\)) have been associated with depressive behaviors, and targeting these receptors is of therapeutic interest [158].
Knockdown of hippocampal PPAR-γ was linked with behavioral changes, reduced neurogenesis, and neuronal differentiation in mouse models [159]. Disrupting the regulation of PPAR-δ by non-coding RNA promoted depressive-like behaviors [160]. Interestingly, venlafaxine, an SNRI, has been shown to require activation of PPAR for antidepressant effects [161]. Because the reduced activity of PPAR is associated with depressive behaviors, increased expression and activation of PPAR have been the focus for antidepressant treatment.

PPAR-γ agonists used in combination with simvastatin improved behavioral effects and had anti-inflammatory effects in rodent models of depression. Pioglitazone is a PPAR-γ agonist that normalized the stress-induced increase in tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6), and interleukin 1-beta (IL-1β) expression levels, and in hippocampal astrocytic activation [162]. It also decreased depressive-like behaviors in a lipopolysaccharide (LPS) model [163]. Rosiglitazone is another PPAR-γ agonist that attenuated neuroinflammation in stressed mice [164], suggesting that both agonists had antidepressant and anti-inflammatory activity. Interestingly, expression data from MDD patients showed that PPAR inhibits inflammatory factors and reactive oxygen species [165].

PPAR is involved in neurogenesis and cellular and behavior function that is associated with depression, therefore modulating PPAR could be an important therapeutic avenue for further research [166]. Using PPAR agonists with either statins or SNRIs improved the anti-depressive activity of these drugs in preclinical models, which proved to be an important mechanism in their antidepressant activity [161–163]. The development of PPAR agonists should be strongly considered. Combinatorial therapy should be further explored in the clinic, where individuals who are already administered SSRI, SNRI, or statins may benefit from adding a PPAR agonist to their regimen.

4.4. G-Protein-Coupled Receptor 39

Zinc deficiency and decreased expression of the zinc sensing receptor G-protein-coupled receptor 39 (GPR39) are associated with MDD [167]. When GPR39 was silenced in a mouse model, increased anxiety-like and depressive-like behaviors, increased passive coping, and treatment resistance to MAOI were observed [168]. On the other hand, there is evidence that agonizing the GPR39 receptor is associated with antidepressant effects. The GPR39 agonist, TC-G 1008, induced prolonged antidepressant-like effects compared to acute administration of imipramine, ZnCl2, or the NMDAR antagonist MK-801 [169]. Ghrelin is a hunger-associated hormone and endogenous GPR39 agonist. Ghrelin administration reduced neuroinflammation and alleviated depressive-like behaviors induced by myocardial infarction in rats [170]. These data indicate that supplementing zinc [171] or targeting the zinc sensing receptors are potential approaches to treat MDD. However, zinc supplementation has been accompanied by adverse events including chills, fever, vomiting, heartburn, and shortness of breath [172]. These symptoms are similar to those reported by clinically available antidepressants [47,64] and could result in enhanced adverse effects if combined with other antidepressants. More preclinical studies are necessary to confirm the mechanisms underlying behavioral findings.

4.5. Metabotropic Glutamate Receptors

Metabotropic glutamate receptors (mGluR) are G protein-coupled receptors that mediate glutamate response through second messenger systems. Targeting specific subtypes of mGluRs has shown antidepressant potential.

mGluR5 localizes in the postsynaptic membrane and modulates synaptic excitability and plasticity. mGluR5 played a crucial role in long-term depression (LTD) by mediating paired-pulse low-frequency stimulation LTD in the hippocampus [173]. It increased excitability and NMDAR activity that is often associated with anxiety and hyperactivity [174], and mediated the rapid antidepressant effect of ketamine [175]. mGluR1/5 might play an important role in regulating synaptic activity. Depressive-like behaviors were observed in mice when the retinoid X receptor gamma, the receptor that promotes mGluR1/5 mediated response, was silenced in mice [176]. In a mGluR5 knockout model, mice lacking
mGluR5 were more susceptible to depressive-like behavior. Rescuing mGluR5 expression in the nucleus accumbens decreased depressive-like behaviors in mice [177]. This finding emphasizes the crucial role of mGluR5 expression in stress resilience and the potential of targeting mGluR5 as a mechanism of antidepressant action. Interestingly, in a clinical trial, basimglurant, a selective negative mGluR5 allosteric modulator improved Montgomery-Asberg Depression Rating Scale, and Depressive Symptomatology–Self-Report of MDD patients at the secondary endpoint of the trial [178].

mGluR2/3 is elevated in animal models of chronic stress with neuronal damage in the hippocampus, suggesting that the mGluR2/3 pathway promoted neuronal damage and neuron viability [179]. Reducing the activity of mGluR2/3 using negative allosteric modulators [180] or mGluR2/3 antagonists, LY341495 [181] and LY3020371 [182] produced antidepressant effects in mice. Interestingly, the combination of (2R,6R)-HNK, a ketamine metabolite, with LY341495 elicited the same antidepressant effect as ketamine with reduced adverse effects [183].

mGluRs-mediated modulation on synaptic transmission can potentially have a protective effect on susceptibility to the effects of chronic stress [174]. mGluRs can also be used as an adjuvant or in combinatorial therapy to reduce the side effects of ketamine-based antidepressant therapy without hindering the efficacy of ketamine [183]. These studies suggest that mGluRs may have both a protective and therapeutic effect against the development of depressive behaviors. Clinical trials are necessary to determine the efficacy of mGluR treatments alone or with other clinically available antidepressants.

4.6. Galanin Receptors

Galanin is a neuropeptide commonly found in neurons of the CNS that binds to three different galanin receptor (GALR) subtypes that can form hetero or homodimers. GALR2 mediates excitatory signaling while GALR1 and GALR3 inhibit it. Activation of GALR2 has antidepressant effects, while GALR1 and GALR3 enhanced depressive-like behaviors [184–186].

Recently, investigation on the underlying molecular mechanism of these receptors in depression has involved using the synthesized galanin analog GAL(1–15), an active N-terminal fragment of galanin [187]. GAL(1–15) promoted depressive-like behaviors in mice by binding to the GALR1-GALR2 heterodimer [188]. However, administration of the 5-HT1AR agonist 8-OH-DPAT, or SSRI fluoxetine [189] in combination with GAL(1–15), reduced depressive-like behaviors, and this effect was blocked by inhibition of the 5HT1AR [190]. The GALR2 antagonist, M871, increased depressive behaviors and increased anxiety-like behaviors in rats [191] while the administration of the GAL2 agonist AR-M1896 [192] or an active galanin analog [193] produced antidepressant effects. Altogether, this indicates that targeting GALR1-GALR2-5-HT1AR heteroreceptor complexes might be a promising future therapeutic strategy to treat depression.

5. Potential Antidepressants Targeting Biological Processes

Another approach to the development of antidepressant treatment is to target broad pathways and biological processes instead of specific receptors. In doing so, dysregulated cellular and physiological effects can be treated. In this section, we focus on biological processes that are known to be involved in the development of depression, such as inflammation, the HPA axis, cholesterol biosynthesis, and gut microbiota. We focus on reports that indicate strong antidepressant potential. These agents and processes are discussed in this section and summarized in Supplementary Tables S3 and S4.

5.1. Inflammation

There is a strong link between inflammation and depressive disorders. MDD patients often have an elevated immune response [194] and pro-inflammatory factors [195] such as TNF-α [196], C-reactive protein (CRP), IL-6, and interleukin-1 receptor antagonist (IL-1ra) [197], while patients with somatic and inflammatory disorders have an increased risk of developing MDD [198]. Patients who received pro-inflammatory treatments for
Somatic diseases are likely to develop depressive symptoms [199]. This bidirectional relationship between inflammation and MDD indicates that anti-inflammatory agents are a potential therapeutic for MDD.

Currently used anti-inflammatory drugs have produced antidepressant effects in patients. Clinical trials on the cyclooxygenase (COX)-2 inhibitor indicate that anti-inflammatory agents can reduce depressive symptoms in MDD patients [200]. The release of cytokines promotes an increase in COX-1 and COX-2 activities, leads to prostaglandins synthesis, and further prolongs the inflammation [201]. Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit COX-1 and 2 and prevent the cascade of COX enzymatic reactions [202].

Preclinical studies have suggested that inhibitors of COX-2 have antidepressant effects in animal models. Lumiracoxib is a COX-2 inhibitor that normalized corticosterone-induced glutamatergic currents in the amygdala, reducing anxiety-like behaviors in mice [203]. Nimesulide, a COX-2 inhibitor with antioxidant and anti-inflammatory properties induced antidepressant-like effects and downregulated the production of inflammatory factors induced by oxidative stress [204].

In clinical studies, both COX-1 and 2 antagonists have been effective in reducing depressive symptoms. Diclofenac improved depressive symptoms in chronic pain patients [205]. Celecoxib, a selective COX-2 inhibitor, combinatorial treatment with SSRI twice a day for 8 weeks was more effective than SSRI alone in alleviating depressive symptoms of MDD patients [206]. Improved cognitive function and emotion processing after six weeks of treatment have also been reported [207].

Over-the-counter NSAIDs including ibuprofen, aspirin, and naproxen have been associated with antidepressant effects. Ibuprofen is a COX-2 inhibitor that is commonly used to treat pain and fever [208]. Ibuprofen reduced inflammation [209], and chronic stress-induced depressive-like behaviors [210] in mice by downregulating BDNF in the hippocampus [211]. Aspirin is an NSAID that inhibits COX-1. Depressive patients treated with a combined treatment of aspirin and minocycline had a significant improvement in their clinical response rate, indicating that aspirin has the potential to enhance antidepressant efficacy [212]. Naproxen is another over-the-counter NSAID that reduces pain and fever by non-selective inhibition of both COX-1 and COX-2 [213] that reduced symptoms in osteoarthritis patients [214]. Interestingly, neither aspirin nor naproxen produced antidepressant effects in elderly patients [215,216], indicating that there the limitations to this treatment that should be further defined.

Clinical trials on the TNF-α inhibitor etanercept indicate that additional anti-inflammatory agents can also reduce depressive symptoms in MDD patients [217]. Infliximab, a TNF-α antagonist, inhibited TNF receptor (TNFR)/nuclear factor κB (NF-κB) signaling and depressive symptoms in MDD patients who were exposed to early life stress [218]. Minocycline is a tetracycline antibiotic that mediated neuroprotective effects and alleviated depressive symptoms by modulating CRP and IL-6 [219–221]. Medications used to treat inflammatory conditions, such as psoriasis, (guselkumab [222] and ustekinumab [223]), rheumatoid arthritis (etanercept [224] and tocilizumab [225]), hidradenitis suppurativa (adalimumab [226]) also improved depressive symptoms in these patients.

Administration of N-acetyl cysteine (NAC), an antioxidant, to mice reduced depressive-like behaviors and restored the corticosterone levels in the amygdala [227]. It also provided a neuroprotective effect against oxidative stress and DNA damage in the hippocampus due to NAC antioxidant and anti-inflammatory effects [228]. Similarly, modafinil, an anti-epileptic medication, exerted neuroprotective effects through its anti-inflammatory properties [229].

The strong association of inflammatory diseases, inflammation, and depression emphasizes the importance of the inflammatory system in depression and the deep connection of systemic and neuroinflammation with mental health [230]. Utilizing the appropriate anti-inflammatory agents to manage chronic inflammatory diseases may be critical to prevent depression as a comorbidity. It may also be prudent to reduce systemic inflammation for acute inflammatory indications to prevent the development of depressive symptoms [231].
Utilizing anti-inflammatory agents to reduce heightened basal inflammatory levels should also be further explored in depression cases independent of inflammatory disease. Targeting specific inflammatory cytokines, the NF-κB signaling pathway, or targeting COX could be potential therapeutic strategies to treat a broad population of patients [218,232]. The unique reactivity of the inflammatory system could be one aspect of why some people are more prone to MDD than others.

5.2. Hypothalamic-Pituitary-Adrenal Axis

HPA axis is the major neuroendocrine system in the CNS that mediates the stress response [233]. Prolonged stress may lead to hyperactivation of the HPA axis and increased production of the corticotropin-releasing hormone in the positive feedback loop, suggesting that blocking the hyperactivation of the HPA axis is a key factor in preventing stress-induced depression [234,235].

The mineralocorticoid receptor (MR) and glucocorticoid receptor (GR) regulate the HPA axis by triggering the stress response. MRs are primarily expressed in the hippocampus and PFC and play a major role in memory and executive function [236]. Genetic variants of MR have been associated with susceptibility or resilience to depressive symptoms. Individuals with certain haplotypes are more susceptible to early life stressors [237] or have sex-dependent susceptibility or resilience to childhood trauma [238] and to the development of MDD [239].

There is an inverse correlation between MR and depression; chronic stress downregulates MR and antidepressants increase MR expression. Increased MR decreases the activity of the HPA axis, to promote reduced anxiety and stress-coping mechanisms [240]. Depressive patients treated with an MR agonist, fludrocortisone, had significant improvement in executive function and memory. Importantly, this mechanism resulted in stimulation of MR without impairing cortisol secretion from the adrenals, which could cause numerous and widespread adverse effects [241]. MR antagonist, spironolactone, decreased stress-induced amygdala activity and improved cognitive function in MDD patients [242], but TRD patients were unresponsive to treatment [243] indicating that MR dysfunction could contribute to TRD. However, over-activation of MR increases the risk of prolonged inflammation in the brain [239], which increases M1 microglia. Since chronic stress induces remodeling of M1 microglia in the PFC [244], this could contribute to the development of MDD and pathological damage in the brain [245]. To maintain homeostasis in the brain, GRs are expressed to dampen MR function by reducing inflammation. This reflects the importance of the MR:GR ratio in the brain, and the inherent risks with targeting MR to treat MDD [246].

Glucocorticoid (GC) is a hormone synthesized and regulated by the HPA axis in response to stress and mediated by GR [247]. Similar to MRs, impaired or dysregulated GRs can lead to the development of MDD [248]. The regulation of GRs by the Abelson helper integration site 1 (Ahi1) gene is involved in depressive behaviors. A heterozygous Ahi1 knockout mouse exhibited stress resilience [249], while a homozygous knockout of Ahi1 showed depressive-like symptoms [250], and reduced the efficacy of antidepressants [251]. FK506 binding protein 51 (FKBP5) is another GR regulator that prevents GC binding, leading to hyperactivation of the HPA axis [252]. FKBP5 knockout mice displayed HPA axis inhibition with depressive-like behaviors induced by chronic restraint stress [253]. High expression of FKBP5 was positively correlated with increased depressive symptoms and reduced antidepressant effects in patients. Overexpression of GRs has been associated with stress resilience in animal models. Rodents overexpressing MR were less likely to develop helplessness behaviors compared to rodents with reduced GR expression [254,255]. Clinically, GR agonists prednisone and dexamethasone lowered cortisol levels in MDD patients who experienced early life stress [256]. GR regulators should be further considered as potential novel therapeutics for the treatment of depression.

Increased activity of the HPA axis also leads to psychotic major depression (PMD) [257]. Compared to MDD patients, higher cortisol levels and hyperactivity of the HPA axis
were reported in PMD patients [258]. Mifepristone, a GR antagonist, decreased psychotic symptoms and cortisol levels specifically in PMD patients [259]. Mifepristone could also treat alcohol dependence-induced depression and cognitive deficits with no major side effects [260].

Arginine vasopressin type 1B receptor (V1B) has also been a therapeutic target in MDD treatments. ABT-436, a V1B antagonist, decreased saliva cortisol, serum cortisol, and free cortisol levels of depressed patients 8 h after administration, and alleviated depressive symptoms [261]. Another V1B antagonist, TS-121, decreased cortisol levels and depressive symptoms in TRD patients with hyperactive HPA axis [262].

The HPA axis has a defined role in the stress response and in the development of depression. Inhibition of the HPA axis or modulation of MRs and GRs can play a role in resilience to chronic stress [254]. Preclinical models manipulating the expression of MR and GR show promising results, however, this is a difficult concept to mimic in the clinic. Therefore, future studies should use haplotype information to stratify patient populations for alternative treatment of depression or determine if preventative therapies are suitable for those susceptible to the development of MDD. Stimulation of GR could be a potential therapy to treat MDD patients specifically exposed to early life stress [256]. However, the safety and long-term efficacy of GR stimulation are unknown. Although suppression of MR reduced stress-related amygdala activities, it was not effective in TRD patients reflecting a limitation to this potential treatment [243]. Drugs targeting MRs and GRs have not been explored to their fullest potential. Therefore, one potential avenue is to determine the safety and efficacy of targeting these receptors.

5.3. Cholesterol Biosynthesis Pathway

Statins are hydroxymethylglutaryl-CoA reductase inhibitors. Since this enzyme plays an important role in the cholesterol biosynthesis pathway, statins possess a hypolipidemic effect and are thus prescribed to patients with cardiovascular disorders [263]. Statins were clinically shown to reduce inflammation with a fast and early efficacy [264]. Recently, numerous preclinical and clinical studies tested the potential antidepressant and neuroprotection effects of these inhibitors.

Simvastatin reduced depressive-like behaviors in mice and downregulated glial activation and pro-inflammatory cytokines [265]. This suggests that the antidepressant potential of simvastatin could be mediated by a decrease in neuroinflammation and by the inhibition of the NF-κB pathway [265]. This antidepressant effect was also observed in high-fat diet mice along with an attenuation of neuroinflammatory factors in the hippocampus [266]. In ovariectomized rats, simvastatin decreased depressive-like behaviors, downregulated the expression of toll-like receptors 2 and 4, reduced IL-1β and IL-18 expression, and limited microglia activation in the hippocampus [267]. When co-administered with an opioid receptor antagonist (naloxone), the antidepressant effect of simvastatin was reduced, suggesting that opioid receptors could be involved in statin’s mechanism of action [268].

Atorvastatin decreased depressive-like behaviors in several mouse models of depression by decreasing TNF-α, IL-1β, and NF-κB p65, or by increasing hippocampal BDNF [269–271]. The antidepressant effect of atorvastatin and simvastatin are dependent on the agmatine and imidazoline receptors; pretreatment of mice with an agmatine receptor agonist potentiated the effect of both statins, while the blockade of imidazoline receptors reduced efficacy [272]. Similar to atorvastatin, lovastatin might be preferred for patients with diabetes and depressive symptoms [273].

Statins are one of the most widely prescribed drugs in the world [274], yet we do not fully understand their potential in reducing depressive symptoms. With a large number of patients taking statins throughout the world, future studies should collect data to determine if there are mood-altering effects, and if these effects are associated with specific comorbidities or if there are race, age, or sex-specific effects.

Since the ultimate result of statins is the inhibition of L-mevalonate production through inhibiting hydroxymethylglutaryl-CoA reductase, this might be an underlying mechanism
of antidepressant action. To further test the role of L-mevalonate in depression, future studies should also investigate amino-bisphosphonates which affect the same pathway. Amino-bisphosphonates inhibit L-mevalonate production, and have been used for osteoporosis, Paget’s disease, and cancer treatment [275,276], though their antidepressant or mood-altering effects have not been reported. The combination of amino-bisphosphonates with statins might lead to more L-mevalonate inhibition, which might increase the efficacy of the treatment.

5.4. Gut Microbiota

The symbiotic intestinal microbiota has been associated with several important processes in the body, including immunity and metabolism. More recently, an association between gut microbiota and depression has been uncovered, with significant gut microbiota variation between MDD and healthy patients [277]. Pre-clinical and clinical trials summarizing these findings will be reported in this section.

Disruption of microbiota is associated with increased depressive-like behaviors in mice. Fecal microbiota transplantation from chronic social defeat stress (CSDS)-susceptible mice increased depressive and anhedonia-like behaviors in recipient mice, along with an increase in IL-6 levels [278]. Lactobacillus intestinalis and Lactobacillus reuteri were suggested to be responsible for these depressive-like behaviors [278]. When similar microbiota transplantation was used in resilient Ephx2 knock-out mice, increased depressive-like behaviors, anhedonia, and IL-6 levels were reported [279]. Faecalibaculum rodentium was reported to cause the increase in stress susceptibility [279]. Mice subjected to antibiotic-induced microbiome depletion were resilient to CSDS-induced anhedonia. This antibiotic cocktail treatment increased proteobacteria with significant alterations in microbiota [280].

Prebiotic or probiotic treatment could be important to consider for the treatment of depression. Mice treated with the two prebiotics fructo-oligosaccharides (FOS) and galacto-oligosaccharides (GOS), either as mono or combination therapy, showed decreased depressive-like behaviors and anxiety-like behaviors [281]. Additionally, corticosterone release was decreased in GOS and FOS+GOS treated mice, with downregulation of proinflammatory cytokine levels reported in the latter group [281].

Bifidobacterium was detected in the gut of mice resilient to CSDS [282] and treatment with Bifidobacterium improved social interaction, normalized IL1-B levels in the PFC, and normalized the changes in gut microbiota composition [283]. Lower corticosterone levels were reported in the serum of mice treated with Bifidobacterium breve and increased butyrate levels were found in the cecum of mice treated with Bifidobacterium longum subsp. infantis. Both treatments enhanced chronic-stress-induced microbial dysbiosis [284].

In clinical studies, probiotic treatment significantly improved the mood of patients diagnosed with mild to moderate depression [285]. Patients with irritable bowel syndrome treated with the probiotic Bifidobacterium longum reported a significant reduction in depression score compared to the placebo group [286]. This score was also decreased in MDD patients treated with probiotic supplements, with downregulated serum hs-CRP, and increased plasma total glutathione in treated patients [287]. Bifidobacterium longum 1714 administration significantly reduced stress levels, attenuated anxiety, and improved memory in healthy volunteers exposed to psychological and physiological stressors [288].

In additional studies, however, treatment with either probiotics or prebiotics did not significantly improve depressive symptoms or scores [289–293]. Either differences in responsiveness is due to the parameters of the study, or like other antidepressants, there are individuals who respond to some treatments, but not to others. This conflicting reporting stresses (1) the importance of further elucidating the etiology of depression and the rationale for individuals who are resilient and (2) the urgent need for additional randomized, double-blind, placebo-controlled trials with larger sample sizes to confirm or refute the antidepressant potential of pre/probiotics.
6. Potential Antidepressants from Natural Products

A remarkable number of plant extracts and natural products are reported to have antidepressant potential. Notably, few clinical trials have been conducted on natural products for most diseases, including psychiatric diseases. The lack of rigorous studies remains a major limitation in determining the efficacy of these potential therapeutic agents. Natural products that are reported to have preclinical or clinical antidepressant effects are discussed below and are summarized in Supplementary Tables S4 and S5.

6.1. Plants

Natural products are used by 75% of the world for routine health care, cancer treatment, multiple sclerosis, and infectious diseases. Many of these products including saponins, triterpenoids, and flavonoids have antidepressant potential through the inhibition of serotonin, norepinephrine, and dopamine transporters [294,295]. Others inhibit monoamine oxidase [296] and increase hippocampal dopamine levels [297,298]. Traditional Chinese medicinal plants that reduce depressive symptoms have a similar mechanism to antidepressant prescription drugs. Here, we will highlight the most recent preclinical in vivo studies demonstrating the antidepressant potential of natural products. For a comprehensive review of medicinal plants used for depression treatment, we recommend Moragrega et al. [299].

Plants used in traditional Chinese medicine were shown to target the 5-HT1a receptor [300] and transporter [301], and enhance synaptic plasticity through AMPAR and mTOR signaling [302]. Two flavonoids extracted from Tilia americana, a plant grown in North America that has been used to treat sleep disorders [303], showed significant antidepressant effects through the 5-HT1A and 5-HT2A receptors [304]. Panax ginseng, Polygala tenuifolia, Shen Yuan, and Fructus aurantii, are used in traditional Chinese medicine and were shown to activate BDNF and rescue rodents from depressive-like behaviors [305–308]. The herbal formula traditionally used in Thailand, KleeB Bua Daeng, affected BDNF expression and proinflammatory factors in the PFC and the hippocampus [309]. Silexan, an essential oil extracted from lavender, delivered an antidepressant effect by increasing synaptogenesis and phosphorylation of the transcription factor cAMP response element-binding (CREB) [310].

The following plants and extracts are reported to have both anti-inflammatory and antidepressant properties. Schisandra chinensis [311], helicid [312], panaxynol [313], and safflower extract [314] regulated various factors in the NF-kB and toll-like receptor 4–nucleotide-binding and oligomerization domain-like receptor 3 (NLRP3) signaling pathways. The honey fungus Armillaria mellea [315] reduced TNF-α and IL-1β [316]. Radix polygonae increased autophagy and reduced neuroinflammation [317]. Schisandra chinensis [311], Cistanche tubulosa [318], and Sophora alopecuroides [319] promoted diverse intestinal microbiome.

The role of PPAR in the antidepressant potential of natural products has been reported in carnosic acid, oridonin, and icariin. Carnosic acid [320] and oridonin [321] rescued mice from depressive-like behaviors by increasing PPAR-γ expression and adiponectin. Icariin, used in traditional Chinese medicine, attenuated M1 microglia in stressed mice by activating PPAR-γ. This resulted in reduced pro-inflammatory proteins, Aβ plaques, and M1 microglia in the hippocampus and the PFC of stressed mice [322].

Numerous plant extracts showed antidepressant-like effects in behavioral tests conducted on mice, but more research is needed to further study the specific mechanisms of action. These include: Woodfordia fruticose leaf extract [323], myrsinoic acid B from Myrsine coriacea [324], parsley [325], Bacopa monnieri (Linn.) Wettst [326], Salvia officinalis, and Lippia triphylla [327].

Plant extracts can target multiple receptors, distinct biological processes, or have widespread molecular and behavioral effects [299]. Several plant extracts have behavioral effects similar to current antidepressant drugs [328]. However, these antidepressant effects are often reported without a proposed underlying mechanism. Therefore, further studies on efficacious plant extracts should be conducted to determine mechanisms underlying...
antidepressant effects. For some plant extracts, there are proposed mechanisms of action, such as helicid and *Sophora alopecuroides*. Antidepressant effects could be produced by a reduction in M1 microglia or reduction of inflammatory factors \[312,329\]. These products should be further explored in rigorous clinical studies to determine their efficacy in humans.

### 6.2. N-3 Polyunsaturated Fatty Acids

The cell membrane is composed of polyunsaturated fatty acids (PUFAs), which have a crucial role in physiological, neuronal, and metabolic function \[330\]. PUFAs are classified as N-3 and N-6 fatty acids and are thought to promote neurogenesis, anti-inflammatory effects, and to modulate neurotransmission \[331\]. Important PUFAs including eicosapentaenoic acid (EPA), arachidonic acid (AA), and docosahexaenoic acid (DHA) are needed to biosynthesize endocannabinoids, endogenous ligands of the cannabinoid receptors that play a crucial role in synaptic plasticity and CNS development \[332\]. Imbalance in these acids often leads to neuroinflammation in important brain regions \[333\]. Additionally, dysregulation of DHA/EPA or AA levels negatively impacts serotonin levels and limbic system regulation by the frontal cortex \[334\]. Contradictory evidence currently exists, and more studies are necessary to understand the complexities and potential of PUFAs as antidepressant agents. Here, we provide current clinical studies that primarily demonstrate the antidepressant effects of PUFAs.

Treatment with N-3 PUFAs has improved depressive symptoms in elderly patients, patients with acute myocardial infarction, and patients diagnosed with heart-failure depression \[335–337\]. N-3 PUFAs antidepressant effect was delivered in a dose-dependent manner \[338\]. Additionally, combinatorial therapy of N-3 PUFAs and ascorbic acid \[339\] or sertraline \[340\] improved symptoms of depression. EPA and DHA reduced depressive symptoms with a superior overall clinical benefit of EPA compared to DHA \[341–343\].

There are numerous clinical reports of no significant antidepressant effect from PUFAs \[344–349\]. Interestingly, a majority of these studies were conducted in children, adolescents, or elderly populations. Bai et al. reported mixed findings on the antidepressant potential of N-3 PUFAs in treating MDD elderly patients \[350\]. In patients with cardiovascular diseases comorbid MDD, no significant overall effect was reported on depressive symptoms with N-3 PUFAs treatment compared to placebo. However, this treatment reduced core depression symptoms in severe MDD patients \[351\], suggesting that N-3 PUFAs treatment may be more effective in treatment-resistant populations.

There are currently an equal number of studies indicating the antidepressant effect of N-3 PUFAs as there are studies without an antidepressant effect. The difference in responsiveness to N-3 PUFAs suggests it may be important to consider specific demographics such as age and other health issues of the patient. Although DHA supplementation is a common practice and available over-the-counter, the clinical benefit and therapeutic dosage remain unclear and must be confirmed with controlled clinical trials. As such, prioritizing clinical trials should be considered for MDD patients, or for individuals who have risk factors for developing MDD.

### 6.3. Resolvins

Resolvins are molecules belonging to the family of specialized pro-resolving lipid mediators \[352\]. Enzymatically produced in organs and fluids, resolvins are derived from acids including DHA (RvD1 and RvD2) and EPA (RvE1, 2 and 3) \[353\]. RvDs and RvEs were recently shown to induce antidepressant effects in multiple pre-clinical studies discussed below.

Intracerebroventricular (ICV) injection, PFC infusion, or hippocampal infusion of RvD1, RvD2, or AT-RvD1 reduced depressive-like behaviors \[354–356\]. This antidepressant effect was reversed when two antagonists, formyl peptide receptor 2/lipoxin A4 receptor (FPR2/ALX) and GPR18, were administered, or with mammalian target of rapamycin complex 1 inhibition by rapamycin \[355\]. Cultured hippocampal neurons had reduced dendritic and axonal length when treated with FPR2/ALX \[357\]. RvD1 activated the
AMPAR and PI3K pathways, while RvD2 activated the mitogen-activated protein kinase kinase (MEK)-ERK pathway [355].

Similar outcomes were reported with EPA-derived resolvins. LPS-induced depressive-like behaviors in mice were reduced after RvE1 and RvE2 ICV injections [358,359]. A ChemR23 (G protein-coupled receptor) agonist reversed depressive-like behaviors, suggesting that ChemR23 agonistic activity is important for RvE1 and RvE2 antidepressant potential [358].

Altogether, these studies demonstrate the antidepressant potential of resolvins. Because administration has primarily been through ventricle or direct brain injection, an important step will be in determining the dosage and efficacy of more convenient delivery methods. As mentioned above, resolvins are derived from DHA, further supporting an exploration into the benefits of DHA supplementation.

7. Conclusions

Here, we have summarized the most recently studied pharmaceutical approaches, including synthetic compounds and natural products to target receptors or biological processes. Current antidepressant treatment options are inadequate for patients, primarily due to adverse effects, delayed onset of antidepressant action, and inadequate efficacy.

One of the major issues underlying inadequate pharmacological treatment is due to an incomplete understanding of the etiology of depression. First-line antidepressants primarily target the serotonin or norepinephrine system, yet it is apparent that molecular mechanisms underlying depression extend beyond monoamines. Prioritizing research efforts on elucidating mechanisms underlying resilience or susceptibility to depression and identifying genetic or epigenetic risk factors is a critical first step to developing novel therapeutics.

MDD is a heterogeneous disease; patients experience unique combinations of symptoms and therefore it is expected that patients would have variable responses and require personalized treatment. Increasing the available pharmaceutical agents will allow clinicians to overcome current obstacles by personalizing treatment based on the patient’s symptoms, risk factors, sex, age, response to prior treatment, and other important factors. As more molecular modulators are identified to have a role in the development of depression, it is important to consider combinatorial therapy addressing multiple dysregulated factors involved in the process.

There are numerous studies that indicate probiotics and natural products have antidepressant potential, yet confounding evidence in both preclinical and clinical studies still exists. One of the major limitations in determining efficacy is the severe lack of large-scale placebo controlled, double-blinded clinical studies. By conducting these studies, more evidence could be generated, which might strengthen the use of these natural products as potential approaches for MDD treatment. Combinatorial therapy can also be tested, which might lead to an enhanced treatment efficacy.

Many of the novel targets described in this review are in early preclinical studies phases of discovery. Prioritizing research on these novel mechanisms could progress to rigorous preclinical and clinical studies in the future, and ultimately lead to the identification of novel targets and improved treatment options.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/life12020196/s1, Table S1: Receptor Targeted in Preclinical Studies; Table S2: Receptors Targeted in Clinical Studies; Table S3: Biological Processes Targeted in Preclinical Studies; Table S4: Biological Processes Targeted in Clinical Studies; Table S5: Preclinical Studies on Natural Products; Table S6: Clinical Studies on Natural Products.

Author Contributions: Conceptualization: E.E., A.Y.Z. and M.T.M.; Investigation: E.E., A.Y.Z. and M.T.M.; Resources: E.E., A.Y.Z. and M.T.M.; Writing: E.E., A.Y.Z. and M.T.M., Editing: M.T.M. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.
Informed Consent Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Mental Disorders. Available online: https://www.who.int/news-room/fact-sheets/detail/mental-disorders (accessed on 19 November 2021).
2. Hillhouse, T.M.; Porter, J.H. A brief history of the development of antidepressant drugs: From monoamines to glutamate. Exp. Clin. Psychopharmacol. 2015, 23, 1–21. [CrossRef] [PubMed]
3. Kessler, R.C.; Petukhova, M.; Sampson, N.A.; Zaslavsky, A.M.; Wittchen, H.U. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int. J. Methods Psychiatr. Res. 2012, 21, 169–184. [CrossRef] [PubMed]
4. Karch, D.L.; Logan, J.; McDaniel, D.; Parks, S.; Patel, N. Surveillance for Violent Deaths—National Violent Death Reporting System, 16 States, 2009. Morb. Mortal. Wkly. Rep. Surveill. Summ. 2012, 61, 1–43.
5. Shaw, D.M.; Camps, F.E.; Eccleston, E.G. 5-Hydroxytryptamine in the hind-brain of depressive suicides. Br. J. Psychiatry J. Ment. Sci. 1967, 113, 1407–1411. [CrossRef]
6. National Collaborating Centre for Mental Health. Depression: The Treatment and Management of Depression in Adults (Updated Edition); British Psychological Society: Leicester, UK, 2010.
7. Fava, M.; Davidson, K.G. Definition And Epidemiology of Treatment-Resistant Depression. Psychiatr. Clin. N. Am. 1996, 19, 179–200. [CrossRef]
8. Hashimoto, K. Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine. Biochem. Pharmacol. 2020, 177, 113935. [CrossRef]
9. McEwen, B.S.; Akil, H. Revisiting the Stress Concept: Implications for Affective Disorders. J. Neurosci. 2020, 40, 12–21. [CrossRef]
10. Torres-Berrio, A.; Morgunova, A.; Giroux, M.; Cuesta, S.; Nestler, E.J.; Flores, C. miR-218 in Adolescence Predicts and Mediates Vulnerability to Stress. Biol. Psychiatry 2021, 89, 911–919. [CrossRef]
11. Fava, M. Diagnosis and definition of treatment-resistant depression. Biol. Psychiatry 2003, 53, 649–659. [CrossRef]
12. Pare, C.M.; Sandler, M. A clinical and biochemical study of a trial of iproniazid in the treatment of depression. J. Neurol. Neurosurg. Psychiatry 1959, 22, 247. [CrossRef]
13. Marshall, E.F.; Stirling, G.S.; Tait, A.C.; Todrick, A. The effect of iproniazid and imipramine on the blood platelet 5-hydroxytryptamine level in man. Br. J. Pharmacol. Chemother. 1960, 15, 35–41. [CrossRef] [PubMed]
14. West, E.D.; Dally, P. Effects of Iproniazid in Depressive Syndromes. Br. Med. J. 1959, 1, 1491–1494. [CrossRef] [PubMed]
15. Davison, A.N. The mechanism of the irreversible inhibition of rat-liver monoamine oxidase by iproniazid (marsilid). Biochem. J. 1957, 67. [CrossRef] [PubMed]
16. Bonnet, U. Moclobemide: Evolution, Pharmacodynamic, and Pharmacokinetic Properties. CNS Drug Rev. 2002, 8, 283–308. [CrossRef] [PubMed]
17. Cusack, B.; Nelson, A.; Richelson, E. Binding of antidepressants to human brain receptors: Focus on newer generation compounds. Psychopharmacology 1994, 114, 599–665. [CrossRef] [PubMed]
18. Owens, M.J.; Morgan, W.N.; Platt, S.J.; Nemeroff, C.B. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J. Pharmacol. Exp. Ther. 1997, 283, 1305–1322. [PubMed]
19. Aree, T. Supramolecular Complexes of β-Cyclodextrin with Clomipramine and Doxepin: Effect of the Ring Substituent and Component of Drugs on Their Inclusion Topologies and Structural Flexibilities. Pharmaceuticals 2020, 13, 278. [CrossRef]
20. Ulrich, S.; Ricken, R.; Adli, M. Tranylcypromine in mind (Part I): Review of pharmacology. Eur. Neuropsychopharmacol. 2017, 27, 697–713. [CrossRef]
21. Okano, M.; Takahata, K.; Sugimoto, J.; Muraoka, S. Selegiline Recovers Synaptic Plasticity in the Medial Prefrontal Cortex and Improves Corresponding Depression-Like Behavior in a Mouse Model of Parkinson’s Disease. Front. Behav. Neurosci. 2019, 13, 176. [CrossRef]
22. Ishikawa, T.; Okano, M.; Minami, A.; Tsumekawa, H.; Satoyoshi, H.; Tsukamoto, Y.; Takahata, K.; Muraoka, S. Selegiline ameliorates depression-like behaviors in rodents and modulates hippocampal dopaminergic transmission and synaptic plasticity. Behav. Brain Res. 2019, 359, 353–361. [CrossRef]
23. Zhang, Z.; Shao, M.; Chen, S.; Liu, C.; Peng, R.; Li, Y.; Wang, J.; Zhu, S.; Qu, Q.; Zhang, X.; et al. Adjunct rasagiline to treat Parkinson’s disease with motor fluctuations: A randomized, double-blind study in China. Transl. Neurodegener. 2018, 7, 14. [CrossRef] [PubMed]
24. Schneider, J.; Patterson, M.; Jimenez, X.F. Beyond depression: Other uses for tricyclic antidepressants. Clevel. Clin. J. Med. 2019, 86, 807–814. [CrossRef] [PubMed]
25. Kerr, G.W.; McGuffie, A.C.; Wilkie, S. Tricyclic antidepressant overdose: A review. Emerg. Med. J. 2001, 18, 236–241. [CrossRef] [PubMed]
26. Ansseau, M.; Ansoms, C.; Beckers, G.; Bogaerts, M.; Botte, L.; De Buck, R.; Dircicq, S.; Dumortier, A.; Janseegers, E.; Owieczka, J. Double-blind clinical study comparing alprazolam and doxepin in primary unipolar depression. J. Affect. Disord. 1984, 7, 287–296. [CrossRef]
27. Montgomery, S.A.; Baldwin, D.S.; Blier, P.; Fineberg, N.A.; Kasper, S.; Lader, M.; Lam, R.W.; Lépine, J.-P.; Möller, H.-J.; Nutt, D.J.; et al. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int. Clin. Psychopharmacol. 2007, 22, 323–329. [CrossRef]

28. Finder, R.M.; Brodgen, R.N.; Speight, T.M.; Avery, G.S. Doxepin Up-to-Date: A Review of its Pharmacological Properties and Therapeutic Efficacy with Particular Reference to Depression. Drugs 1977, 13, 161–218. [CrossRef]

29. Wichniak, A.; Wierzbicka, A.; Walička, M.; Jernáčczyk, W. Effects of Antidepressants on Sleep. Curr. Psychiatry Rep. 2017, 19, 63. [CrossRef]

30. Sateia, M.J.; Buysse, D.J.; Krystal, A.D.; Neubauer, D.N.; Heal, J.L. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American academy of sleep medicine clinical practice guideline. J. Clin. Sleep Med. 2017, 13, 307–349. [CrossRef]

31. Baumeister, H.; Hutter, N.; Bengel, J. Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database Syst. Rev. 2011, 2011, CD008012. [CrossRef]

32. Upward, J.W.; Edwards, J.G.; Goldie, A.; Waller, D.G. Comparative effects of fluoxetine and amitriptyline on cardiac function. Br. J. Clin. Pharmacol. 1986, 26, 399–402. [CrossRef]

33. Bye, C.; Clubley, M.; Peck, A.W. Drowsiness, impaired performance and tricyclic antidepressants drugs. Br. J. Clin. Pharmacol. 1978, 6, 155–162. [CrossRef] [PubMed]

34. Kuenssberg, E.V.; Knox, J.D.E. Imipramine in Pregnancy. Br. Med. J. 1972, 2, 292. [CrossRef] [PubMed]

35. Sloman, L. Myocardial infarction during imipramine treatment of depression. Can. Med. Assoc. J. 1960, 82, 20. [PubMed]

36. Freeman, J.W.; Mundy, G.R.; Beattie, R.R.; Ryan, C. Cardiac Abnormalities in Poisoning with Tricyclic Antidepressants. Br. Med. J. 1969, 2, 610–611. [CrossRef]

37. ter Horst, P.G.; van der Linde, S.; Smit, J.P.; den Boon, J.; van Lingen, R.A.; Janssen, F.G.A.; De Jong-van den Berg, L.T.W.; Wilffert, B. Clomipramine concentration and withdrawal symptoms in 10 neonates. Br. J. Clin. Pharmacol. 2012, 73, 295–302. [CrossRef] [PubMed]

38. Donoghue, J.; Tylee, A.; Wildgust, H. Cross sectional database analysis of antidepressant prescribing in general practice in the United Kingdom, 1993–5. BMJ 1996, 313, 861–862. [CrossRef]

39. Bruno, M.A.D.; Krymchantowski, A.V. Amitriptyline and intraoral devices for migraine prevention: A randomized comparative trial. Arq. Neuro-Psiquiatr. 2018, 76, 213–218. [CrossRef]

40. Everitt, H.; Baldwin, D.S.; Stuart, B.; Lipinska, G.; Mayers, A.; Malizia, A.L.; Manson, C.C.; Wilson, S. Antidepressants for insomnia in adults. Cochrane Database Syst Rev 2018, 5, Cd010753. [CrossRef]

41. Shah, Y.D.; Stringel, V.; Pavkovic, I.; Kothare, S.V. Droxepin in children and adolescents with symptoms of insomnia: A single-center experience. J. Clin. Sleep Med. 2020, 16, 743–747. [CrossRef]

42. Anton, R.F.; Latham, P.; Voronin, K.; Book, S.; Hoffman, M.; Prisciandaro, J.; Bristol, E. Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients with Alcohol Withdrawal Symptoms: A Randomized Clinical Trial. JAMA Intern. Med. 2019, 179, 47–56. [CrossRef] [PubMed]

43. Falk, D.E.; Ryan, M.L.; Fertig, J.B.; Devine, E.G.; Cruz, R.; Brown, E.S.; Burns, H.; Salloum, I.M.; Newport, D.J.; Mendelson, J.; et al. Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and Safety. Alcohol. Clin. Exp. Res. 2019, 43, 158–169. [CrossRef] [PubMed]

44. Malberg, J.E.; Eisch, A.J.; Nestler, E.J.; Duman, R.S. Chronic Antidepressant Treatment Increases Neurogenesis in Adult Rat Hippocampus. J. Neurosci. 2006, 26, 103–109. [CrossRef]

45. Encinas, J.M.; Vaathokari, A.; Enoklopo, G. Fluoxetine targets early progenitor cells in the adult brain. Proc. Natl. Acad. Sci. USA 2006, 103, 8233–8238. [PubMed]

46. Wang, J.-W.; David, D.; Monckton, J.E.; Bataglia, F.; Hen, R. Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J. Neurosci. Off. J. Soc. Neurosci. 2008, 28, 1374–1384. [CrossRef]

47. Papakostas, G.I. Tolerability of modern antidepressants. J. Clin. Psychiatry 2008, 69 (Suppl. E1), 8–13. [CrossRef]

48. Jing, E.; Straw-Wilson, K. Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: A narrative literature review. Ment. Health Clin. 2016, 6, 191–196. [CrossRef]

49. Ji, O.S.; Karalis, P.G.; Daas, M.; Condon, J. Gynecomastia Associated With Citalopram. Prim. Care Companion CNS Disord. 2019, 21, 27311. [CrossRef]

50. Goldstein, B.J.; Goodnick, P.J. Selective serotonin reuptake inhibitors in the treatment of affective disorders—III. Tolerability, safety and pharmacoeconomics. J. Psychopharmacol. 1998, 12, 55. [CrossRef]

51. Dvovjovic, A.; Perkovic, M.N.; Sagud, M.; Erjavec, G.N.; Peles, A.M.; Strac, D.S.; Pivac, N. Effect of vortioxetine vs. escitalopram on plasma BDNF and platelet serotonin in depressed patients. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2021, 110, 100106. [CrossRef]

52. Shuto, T.; Kuroiwa, M.; Sotogaku, N.; Kawahara, Y.; Oh, Y-S.; Jang, J.-H.; Shin, C.-H.; Ohnishi, Y.N.; Hanada, Y.; Miyakawa, T.; et al. Obligatory roles of dopamine D1 receptors in the dentate gyrus in antidepressant actions of a selective serotonin reuptake inhibitor, fluoxetine. Mol. Psychiatry 2020, 25, 1229–1244. [CrossRef] [PubMed]
54. Zhang, X.; Zhu, L.-B.; He, J.-H.; Zhang, H.-Q.; Ji, S.-Y.; Zhang, C.-N.; Hou, N.-N.; Huang, C.-P.; Zhu, J.-H. Paroxetine suppresses re-active microglia-mediated but not lipopolysaccharide-induced inflammatory responses in primary astrocytes. J. Neuroinflammation 2020, 17, 50. [CrossRef] [PubMed]

55. Xu, D.; Wang, C.; Zhu, X.; Zhao, W.; Jiang, B.; Cui, S.; Sun, Y.; Cui, Z. The antidepressant-like effects of fluvoxamine in mice involve the mTOR signaling in the hippocampus and prefrontal cortex. Psychiatry Res. 2020, 285, 112708. [CrossRef] [PubMed]

56. Papakostas, G.I. Serotonin norepinephrine reuptake inhibitors: Spectrum of efficacy in major depressive disorder. Prim. Psychiatry 2009, 16, 16–24.

57. Laoutidis, Z.G.; Kioulos, K.T. Desvenlafaxine for the acute treatment of depression: A systematic review and meta-analysis. Pharmacopsychiatry 2015, 48, 187–199. [CrossRef]

58. Monteleone, F.; Caputo, M.; Tecce, M.F.; Capasso, A. Duloxetine in the treatment of depression: An overview. Cent. Nerv. Syst. Agents Med. Chem. 2011, 11, 174–183. [CrossRef]

59. Palmer, E.C.; Binns, L.N.; Carey, H. Levomilnacipran: A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder. Ann. Pharmacother. 2014. [CrossRef]

60. Spencer, C.M.; Wilde, M.I. Milnacipran. A review of its use in depression. Drugs 1998, 56, 405–427. [CrossRef]

61. Krause-Sorio, B.; Kilpatrick, L.; Siddarth, P.; Ercoli, L.; Laird, K.T.; Aguilar-Faustino, Y.; Millillo, M.M.; Narr, K.L.; Lavretsky, H. Cortical thickness increases with levomilnacipran treatment in a pilot randomised double-blind placebo-controlled trial in late-life depression. Psychogeriatrics 2020, 20, 140–148. [CrossRef] [PubMed]

62. Lu, Y.; Zhang, P.; Zhang, Q.; Yang, C.; Qian, Y.; Suo, J.; Tao, X.; Zhu, J. Duloxetine Attenuates Paclitaxel-Induced Peripheral Nerve Injury by Inhibiting p53-Related Pathways. J. Pharmacol. Exp. Ther. 2020, 373, 453–462. [CrossRef]

63. Meng, J.; Zhang, Q.; Yang, C.; Xiao, L.; Xue, Z.; Zhu, J. Duloxetine, a Balanced Serotonin-Norepinephrine Reuptake Inhibitor, Improves Painful Chemotherapy-Induced Peripheral Neuropathy by Inhibiting Activation of p38 MAPK and NF-κB. Front. Pharmacol. 2019, 10, 365. [CrossRef]

64. Stahl, S.M.; Grady, M.M.; Moret, C.; Briley, M. SNRIs: Their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 2005, 10, 732–747. [CrossRef] [PubMed]

65. Fathallah, N.; Slim, R.; Sarfaris, W.; Hmouda, H.; Salem, C.B. Drug-Induced Hyperglycaemia and Diabetes. Drug Saf. 2015, 38, 1153–1168. [CrossRef] [PubMed]

66. Mekonnen, A.D.; Mills, A.A.; Wilhite, A.L.; Hoffman, T.K. Desvenlafaxine-associated hyperglycemia: A case report and literature review. Ment. Health Clin. 2020, 10, 85–89. [CrossRef] [PubMed]

67. Stahl, S.M. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J. Affect. Disord. 1998, 51, 215–235. [CrossRef]

68. Yamakura, T.; Shimoji, K. Subunit- and site-specific pharmacology of the NMDA receptor channel. Pharmacopsychiatry 1993, 4, 687–690. [CrossRef] [PubMed]

69. Yamakura, T.; Shimoji, K. Subunit- and site-specific pharmacology of the NMDA receptor channel. Prog. Neurobiol. 1999, 59, 279–298. [CrossRef]

70. Lord, B.; Wintmlolders, C.; Langlois, X.; Nguyen, L.; Lovenberg, T; Bonaventure, P. Comparison of the ex vivo receptor occupancy profile of ketamine to several NMDA receptor antagonists in mouse hippocampus. Eur. J. Pharmacol. 2013, 715, 21–25. [CrossRef]

71. Berman, R.M.; Cappiello, A.; Anand, A.; Oren, D.A.; Heninger, G.R.; Charney, D.S.; Krystal, J.H. Antidepressant effects of ketamine in depressed patients. Biochem. Pharmacol. 2000, 47, 351–354. [CrossRef]

72. Murrough, J.W.; Isosfescu, D.V.; Chang, L.C.; Juri, R.K.A.; Green, C.E.; Perez, A.M.; Iqbal, S.; Pillemer, S.; Foulkes, A.; Shah, A.; et al. Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial. Am. J. Psychiatry 2013, 170, 1134–1143. [CrossRef] [PubMed]

73. Serafini, G.; Howland, R.H.; Rovedi, F.; Girardi, P.; Amore, M. The Role of Ketamine in Treatment-Resistant Depression: A Systematic Review. Curr. Neuropharmacol. 2014, 12, 444–461. [CrossRef] [PubMed]

74. Wan, L.-B.; Levitch, C.F.; Perez, A.M.; Brallier, J.W.; Isosfescu, D.V.; Chang, L.C.; Foulkes, A.; Mathew, S.J.; Charney, D.S.; Murrough, J.W. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J. Clin. Psychiatry 2015, 76, 247–252. [CrossRef] [PubMed]

75. Diazgranados, N.; Ibrahim, L.; Brutsche, N.E.; Newberg, A.; Kronstein, P.; Khalife, S.; Kammerer, W.A.; Quezado, Z.; Luckenbaugh, D.A.; Salvadore, G.; et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry 2010, 67, 793–802. [CrossRef] [PubMed]

76. Yang, C.; Shirayama, Y.; Zhang, J.C.; Ren, Q.; Yao, W.; Ma, M.; Dong, C.; Hashimoto, K. R-ketamine: A rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl. Psychiatry 2015, 5, e632. [CrossRef] [PubMed]

77. Zanos, P.; Moaddel, R.; Morris, P.J.; Georgiou, P.; Fischell, J.; Elmer, G.I.; Alkondon, M.; Yuan, P.; Pribut, H.J.; Singh, N.S.; et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 2016, 533, 481–486. [CrossRef]

78. Fukumoto, K.; Toki, H.; Iijima, M.; Hashihayata, T.; Yamaguchi, J.-I.; Hashimoto, K.; Chaki, S. Antidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine. J. Pharmacol. Exp. Ther. 2017, 361, 9–16. [CrossRef]

79. Leal, G.C.; Bandeira, I.D.; Correia-Melo, F.S.; Telles, M.; Mello, R.P.; Vieira, F.; Lima, C.S.; Jesus-Nunes, A.P.; Guerreiro-Costa, L.N.F.; Marback, R.F.; et al. Intravenous arketamine for treatment-resistant depression: Open-label pilot study. Eur. Arch. Psychiatry Clin. Neurosci. 2021, 271, 577–582. [CrossRef]
80. Ionescu, D.F.; Fu, D.-J.; Qiu, X.; Lane, R.; Lim, P.; Kasper, S.; Hough, D.; Drevets, W.C.; Manji, H.; Canuso, C.M. Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients with Major Depressive Disorder Who Have Active Suicide Ideation with Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II). *Int. J. Neuropsychopharmacol.* 2020, 24, 22–31. [CrossRef]

81. Wajis, E.; Aluisio, L.; Holder, R.; Daly, E.J.; Lane, R.; Lim, P.; George, J.E.; Morrison, R.L.; Sanacora, G.; Young, A.H. Esketamine Nasal Spray Plus Oral Antidepressant in Patients with Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2). *J. Clin. Psychiatry* 2020, 81, 10773. [CrossRef]

82. Fu, D.-J.; Ionescu, D.F.; Li, X.; Lane, R.; Lim, P.; Sanacora, G.; Hough, D.; Manji, H.; Drevets, W.C.; Canuso, C.M. Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation with Intent: Double-Blind, Randomized Study (ASPIRE I). *J. Clin. Psychiatry* 2020, 81, 19m13191. [CrossRef]

83. Turner, E.H. Esketamine for treatment-resistant depression: Seven concerns about efficacy and FDA approval. *Lancet Psychiatry* 2019, 6, 977–979. [CrossRef]

84. Zimmermann, K.S.; Richardson, R.; Baker, K.D. Esketamine as a treatment for paediatric depression: Questions of safety and efficacy. *Lancet Psychiatry* 2020, 7, 827–829. [CrossRef]

85. Borsini, F.; Mancinelli, A.; D’Aranno, V.; Evangelista, S.; Meli, A. On the role of endogenous GABA in the forced swimming test in rats. *Psychoneuroendocrinology* 2003, 28, 28–29. [CrossRef]

86. Turner, E.H. Esketamine for treatment-resistant depression: Seven concerns about efficacy and FDA approval. *Lancet Psychiatry* 2019, 6, 977–979. [CrossRef]

87. Fukumoto, K.; Iijima, M.; Funakoshi, T.; Chaki, S. Role of 5-HT1A Receptor Stimulation in the Medial Prefrontal Cortex in the Sustained Antidepressant Effects of Ketamine. *Int. J. Neuropsychopharmacol.* 2018, 21, 371–381. [CrossRef]

88. Agnieszka, P.-P.; Karolina, P.; Andrzej, P. Role of AMPA receptor stimulation and TrkB signaling in the antidepressant-like effect of ketamine co-administered with a group II mGlu receptor antagonist, LY341495, in the forced swim test in rats. *Behav. Pharmacol.* 2019, 30, 471–479. [CrossRef]

89. Olsen, R.W.; Sapp, D.W. Neuroactive steroid modulation of GABA(A) receptors. *Adv. Biochem. Psychopharmacol.* 1995, 95, 57–74. [CrossRef]

90. Sieghart, W. Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes. *Pharmacol. Rev.* 1995, 47, 181–234. [CrossRef]

91. Kaur, U.; Pathak, B.K.; Singh, A.; Chakrabarti, S.S. Esketamine: A glimmer of hope in treatment-resistant depression. *Eur. Arch. Psychiatry Clin. Neurosci.* 2021, 271, 417–429. [CrossRef] [PubMed]

92. Bhagwagar, Z.; Wylezinska, M.; Taylor, M.; Jezzard, P.; Matthews, P.M.; Cowen, P.J. Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor. *Psychoparmacology* 2006, 186, 425–433. [CrossRef] [PubMed]

93. Kosel, M.; Rudolph, U.; Wielepp, P.; Luginbühl, M.; Schlaepfer, T.E. Diminished GABA(A) receptor-binding capacity and a DNA base substitution in a patient with treatment-resistant depression and anxiety. *Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol.* 2004, 29, 347–350. [CrossRef] [PubMed]

94. Epperson, C.N.; Gueorguieva, R.; Czarkowski, K.A.; Stikluss, S.; Sellers, E.; Krystal, J.H.; Rothman, D.L.; Mason, G.F. Preliminary evidence of reduced occipital GABA concentrations in puerperal women: A 1H-MRS study. *Psychopharmacology* 2006, 184, 471–479. [CrossRef] [PubMed]

95. Borsini, F.; Mancinelli, A.; D’Aranno, V.; Evangelista, S.; Meli, A. On the role of endogenous GABA in the forced swimming test in rats. *Pharmacol. Biochem. Behav.* 1990, 34, 275–279. [CrossRef]

96. Kelemen, M.; Rudolph, U.; Wielepp, P.; Luginbühl, M.; Schlaepfer, T.E. Diminished GABA(A) receptor-binding capacity and a DNA base substitution in a patient with treatment-resistant depression and anxiety. *Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol.* 2004, 29, 347–350. [CrossRef] [PubMed]

97. Borsini, F.; Mancinelli, A.; D’Aranno, V.; Evangelista, S.; Meli, A. On the role of endogenous GABA in the forced swimming test in rats. *Pharmacol. Biochem. Behav.* 1990, 34, 275–279. [CrossRef]

98. Turney, C.; Kulkarni, S.K. GABA-mediated modification of despair behavior in mice. *Neurochem. Int.* 2003, 42, 166–171. [CrossRef]

99. Kosel, M.; Rudolph, U.; Wielepp, P.; Luginbühl, M.; Schlaepfer, T.E. Diminished GABA(A) receptor-binding capacity and a DNA base substitution in a patient with treatment-resistant depression and anxiety. *Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol.* 2004, 29, 347–350. [CrossRef] [PubMed]

100. Bhagwagar, Z.; Wylezinska, M.; Taylor, M.; Jezzard, P.; Matthews, P.M.; Cowen, P.J. Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor. *Am. J. Psychiatry* 2004, 161, 368–370. [CrossRef]

101. Aley, K.O.; Kulkarni, S.K. GABA-mediated modification of despair behavior in mice. *Naunyn-Schmiedeberg’s Arch. Pharmacol.* 1989, 339, 306–311. [CrossRef]

102. True, A.F.; Boix, F.; Escorihuela, R.M.; Yañez, P.; Tobeña, A. Sodium valporate reduces immobility in the behavioral ‘depair’ test in rats. *Eur. J. Pharmacol.* 1988, 152, 1–7. [CrossRef]

103. Nishimura, H.; Ida, Y.; Tsuda, A.; Tanaka, M. Opposite effects of diazepam and beta-CCE on immobility and straw-climbing behavior of rats in a modified forced-swim test. *Pharmacol. Biochem. Behav.* 1989, 33, 227–231. [CrossRef]

104. Joca, S.R.; Skalizs, L.L.; Beijamini, V.; Vital, M.A.; Andreatini, R. The antidepressive-like effect of oxcarbazepine: Possible role of dopaminergic neurotransmission. *Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol.* 2000, 10, 223–228. [CrossRef] [PubMed]

105. Lladó-Pelfort, L.; Santana, N.; Ghisi, V.; Artigas, F.; Celada, P. 5-HT1A Receptor Agonists Enhance Pyramidal Cell Firing in Prefrontal Cortex through a Preferential Action on GABA Interneurons. *Cereb. Cortex* 2012, 22, 1487–1497. [CrossRef] [PubMed]
105. Milak, M.S.; Proper, C.J.; Mulhern, S.T.; Parter, A.L.; Kegeles, L.S.; Ogden, R.T.; Mao, X.; Rodriguez, C.I.; Oquendo, M.A.; Suckow, R.F.; et al. A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder. *Mol. Psychiatry* **2016**, *21*, 320–327. [CrossRef] [PubMed]

106. Lur, G.; Fariborzi, M.; Higley, M.J. Ketamine disrupts neuromodulatory control of glutamatergic synaptic transmission. *PloS ONE* **2019**, *14*, e0213721. [CrossRef]

107. Rosa, P.B.; Neis, V.B.; Ribeiro, C.M.; Moretti, M.; Rodrigues, A.L.S. Antidepressant-like effects of ascorbic acid and ketamine involve modulation of GABA and GABAB receptors. *Pharmacol. Rep.* **2016**, *68*, 996–1001. [CrossRef]

108. Frankowska, M.; Filip, M.; Przegalinski, E. Effects of GABAB receptor ligands in animal tests of depression and anxiety. *Pharmacol. Rep.* **2007**, *59*, 645–655.

109. Villiger, J.W.; Taylor, K.M. Buprenorphine: Characteristics of binding sites in the rat central nervous system. *Life Sci.* **1981**, *29*, 2699–2708. [CrossRef]

110. Sad, J.; Villiger, J.W.; Taylor, K.M. Buprenorphine: Characteristics of binding sites in the rat central nervous system. *Life Sci.* **1983**, *33*, 187–189. [CrossRef]

111. Davis, M.P.; Pasternak, G.; Behm, B. Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option. *Drugs* **2018**, *78*, 1211–1228. [CrossRef]

112. Shulman, M.; Wai, J.M.; Nunes, E.V. Buprenorphine Treatment for Opioid Use Disorder: An Overview. *CNS Drugs* **2019**, *33*, 567–580. [CrossRef]

113. Karp, J.A.; Zornberg, G.L.; Lukas, S.E.; Cole, J.O. Buprenorphine treatment of refractory depression. *J. Clin. Psychopharmacol.* **2019**, *39*, 75–80. [CrossRef] [PubMed]

114. Yovell, Y.; Bar, G.; Mashiah, M.; Baruch, Y.; Briskman, I.; Asherov, J.; Lotan, A.; Rigbi, A.; Panksepp, J. Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation: A randomized controlled trial. *Am. J. Psychiatry* **2016**, *173*, 491–498. [CrossRef] [PubMed]

115. Bodkin, J.A.; Zornberg, G.L.; Lukas, S.E.; Cole, J.O. Buprenorphine treatment of refractory depression. *J. Clin. Psychopharmacol.* **1995**, *15*, 49–57. [CrossRef] [PubMed]

116. Zajecka, J.M.; Stanford, A.D.; Memisoglu, A.; Martin, W.F.; Pathak, S. Buprenorphine/samidorphan combination for the adjunctive treatment of major depressive disorder: Results of a phase III clinical trial (FORWARD-3). *Neuropsychiatr. Dis. Treat.* **2019**, *15*, 795. [CrossRef]

117. Fava, M.; Thase, M.E.; Trivedi, M.H.; Ehrich, E.; Martin, W.F.; Memisoglu, A.; Nangia, N.; Stanford, A.D.; Yu, M.; Pathak, S. Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: Two randomized controlled studies. *Mol. Psychiatry* **2020**, *25*, 1580–1591. [CrossRef]

118. Callaghan, C.K.; Rouine, J.; Dean, R.L.; Knapp, B.I.; Bidlack, J.M.; Deaver, D.R.; O’Mara, S.M. Antidepressant-like effects of 3-carboxamido seco-nalmefene (3CS-nalmefene), a novel opioid receptor modulator, in a rat IFN-α-induced depression model. *Brain Behav. Immun.* **2018**, *67*, 152–162. [CrossRef] [PubMed]

119. Belluzzi, J.D.; Grant, N.; Gorsky, V.; Sarantakis, D.; Wise, C.D.; Stein, L. Analgesia induced in vivo by central administration of enkephalin in rat. *Nature* **1976**, *260*, 625–626. [CrossRef]

120. Melo, I.; Drews, E.; Zimmer, A.; Bilket-Gorzo, A. Enkephalin knockout male mice are resistant to chronic mild stress. *Genes Brain Behav.* **2014**, *13*, 550–558. [CrossRef] [PubMed]

121. KNT-127 produces antidepressant-like and antinociceptive effects in mice without producing convulsions. *Behav. Brain Res.* **2019**, *359*, 271–279. [CrossRef] [PubMed]

122. Mitsu moto, Y.; Sato, R.; Tagawa, N.; Kato, I. Rubiscolin-6, a δ-Opioid Peptide from Spinach Rubisco, Exerts Antidepressant-Like Effect in Restraint-Stressed Mice. *J. Nutr. Sci. Vitaminol.* **2019**, *65*, 202–204. [CrossRef]

123. Haj-Mirzaian, A.; Nikbakhlsh, R.; Ramezanazadeh, K.; Rezaee, M.; Amini-Khoei, H.; Haj-Mirzaian, A.; Ghesmati, M.; Afshari, K.; Haddadi, N.-S.; Dehpour, A.R. Involvement of opioid system in behavioral despair induced by social isolation stress in mice. *Mol. Psychiatry* **2020**, *25*, 645–655. [CrossRef]

124. Haddadi, N.-S.; Dehpour, A.R. Involvement of nociceptin/orphanin FQ (N/OFQ) and its receptor in depression and antidepressant effects of ascorbic acid and ketamine. *Genes Brain Behav.* **2017**, *16*, 691–703. [CrossRef] [PubMed]

125. Park, J.Y.; Chae, S.; Kim, C.S.; Kim, Y.J.; Yi, H.J.; Han, E.; Joo, Y.; Hong, S.; Yun, J.W.; Kim, H.; et al. Role of nociceptin/orphanin FQ and nociceptin opioid peptide receptor in depression and antidepressant effects of nociceptin opioid peptide receptor antagonists. *Korean J. Physiol. Pharmacol.* Off. J. Korean Physiol. Soc. *Korean Soc. Pharmacol.* **2019**, *23*, 427–448. [CrossRef] [PubMed]

126. Witkin, J.M.; Dorick-Kehn, L.M.; Benvenga, M.J.; Adams, B.L.; Gleason, S.D.; Knitowski, K.M.; Li, X.; Chaney, S.; Falcone, J.F.; Smith, J.W.; et al. Preclinical findings predicting efficacy and side-effect profile of LY2940094, an antagonist of nociceptin receptors. *Pharmacol. Res. Perspect.* **2016**, *4*, e00275. [CrossRef] [PubMed]

127. Suckow, R.F.; et al. A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder. *Mol. Psychiatry* **2016**, *21*, 320–327. [CrossRef] [PubMed]

128. Wagstaff, A.J.; Ormrod, D.; Spencer, C.M. Tianeptine. *CNS Drugs* **2001**, *15*, 231–259. [CrossRef] [PubMed]

129. Trojan, E.; Chamera, K.; Bryniarska, N.; Kotarska, K.; Leskiewicz, M.; Regul ska, M.; Basta-Kaim, A. Role of Chronic Administration of Antidepressant Drugs in the Prenatal Stress-Induced Nociceptin Response in the Brain of Adult Offspring Rats: Involvement of the NLRP3 Inflamasome-Related Pathway. *Mol. Neurobiol.* **2019**, *56*, 5365–5380. [CrossRef] [PubMed]
129. Pekarskaya, E.A.; Holt, E.S.; Gingrich, J.A.; Ansorge, M.S.; Javitch, J.A.; Canetta, S.E. Tianeptine, but not fluoxetine, decreases avoidance behavior in a mouse model of early developmental exposure to fluoxetine. *BioRxiv* 2021. [CrossRef]

130. Perić, I.; Costina, V.; Findeisen, P.; Gass, P.; Filipović, D. Tianeptine Enhances Energy-related Processes in the Hippocampal Non-synaptic Mitochondria in a Rat Model of Depression. *Neuroscience* 2020, 451, 111–125. [CrossRef]

131. Poleszak, E.; Wośko, S.; Slawińska, K.; Wyska, E.; Szopa, A.; Świąader, K.; Doboszewska, U.; Właż, P.; Właż, A.; et al. Influence of the CB1 and CB2 cannabinoid receptor ligands on the activity of atypical antidepressant drugs in the behavioural tests in mice. *Pharmacol. Biochem. Behav.* 2020, 188, 172833. [CrossRef]

132. Ramirez, N.; Hoetel, N.; Nobile, B.; Voegeli, G.; Nasr, A.; Le Strat, Y.; Courtet, P.; Gorwood, P. Corticotropin releasing hormone receptor CRHR1 gene is associated with tianeptine antidepressant response in a large sample of outpatients from real-life settings. *Transl. Psychiatry* 2020, 10, 378. [CrossRef]

133. Serafini, G.; Advogastro, G.; Canepa, G.; De Berardinis, D.; Valchera, A.; Pompili, M.; Nasrallah, H.; Amore, M. The Efficacy of Bupropion in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review. *Int. J. Mol. Sci.* 2018, 19, 2410. [CrossRef] [PubMed]

134. Van’t Veer, A.; Carlezon, W.A., Jr. Role of kappa-opioid receptors in stress and anxiety-related behavior. *Psychopharmacology* 2013, 229, 435–452. [CrossRef] [PubMed]

135. Förstermann, U.; Sessa, W.C. Nitric oxide synthases: Regulation and function. *Eur. Heart J.* 2012, 33, 829–837. [CrossRef]

136. Morgan, M.M.; Christie, M.J. Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human. *Br. J. Pharmacol.* 2011, 164, 1322–1334. [CrossRef] [PubMed]

137. Casillas-Espinosa, P.M.; Powell, K.L.; O’Brien, T.J. Regulators of synaptic transmission: Roles in the pathogenesis and treatment of epilepsy. *Epilepsia* 2012, 53 (Suppl. 9), 41–58. [CrossRef]

138. Lutz, P.-E.; Kieffer, B.L. Opioid receptors: Distinct roles in mood disorders. *Trends Neurosci.* 2013, 36, 195–206. [CrossRef] [PubMed]

139. Yang, B.; Ren, Q.; Ma, M.; Chen, Q.-X.; Hashimoto, K. Antidepressant Effects of (+)-MK-801 and (-)-MK-801 in the Social Defeat Stress Model. *Pharmacol. Biochem. Behav.* 2020, 229. [CrossRef]

140. Rana, P.; Bagewadi, H.; Banerjee, B.D.; Bhattacharya, S.K.; Mediratta, P.K. Attenuation of oxidative stress and neurotoxicity involved in the antidepressant-like effect of the MK-801(dizocilpine) in Bacillus Calmette-Guerin-induced depression in mice. *J. Basic Clin. Physiol. Pharmacol.* 2020, 31, 20190016. [CrossRef]

141. Nagele, P.; Duma, A.; Kopec, M.; Gebara, M.A.; Parsoei, A.; et al. Nitrous Oxide for Treatment-Resistant Major Depression: A Proof-of-Concept Trial. *BMC Pharmacol. Toxicol.* 2020, 21, 12. [CrossRef] [PubMed]

142. Guimarães, M.C.; Guimarães, T.M.; Hallak, J.E.; Abdurroej, J.; Machado-de-Sousa, J.P. Nitrous oxide as an adjunctive therapy in major depressive disorder: A randomized controlled double-blind pilot trial. *Braz. J. Psychiatry* 2021. [CrossRef]

143. Lavretsky, H.; Laird, K.T.; Krause-Sorio, B.; Heimberg, B.F.; Yeargin, J.; Ercoli, L.M.; Miller, J.P.; et al. Nitrous Oxide and Antidepressant-Like Effects through Neuronal Nitric Oxide Synthase Activation in the Medial Prefrontal Cortex. *Front. Psychiatry* 2020, 11, 837. [CrossRef]

144. Serafini, G.; Adavastro, G.; Canepa, G.; De Berardinis, D.; Valchera, A.; Pompili, M.; Nasrallah, H.; Amore, M. The Efficacy of Bupropion in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review. *Int. J. Mol. Sci.* 2018, 19, 2410. [CrossRef] [PubMed]

145. Mayer, M.L.; Armstrong, N. Structure and function of glutamate receptor ion channels. *Annu. Rev. Physiol.* 2004, 66, 161–181. [CrossRef]

146. Tu, W.; Xu, X.; Feng, L.; Zhong, X.; Zhang, W.; Soundarapandian, M.M.; Bølø, C.; Wang, M.; Jia, N.; Zhang, W.; et al. DAPK1 interaction with NMDA receptor NR2B subunits mediates brain damage in stroke. *Cell* 2010, 140, 222–234. [CrossRef]

147. Nagele, P.; Duma, A.; Kopec, M.; Gebara, M.A.; Parsoei, A.; Walker, M.; Janski, A.; Panagopoulos, V.N.; Cristancho, P.; Miller, J.P.; et al. Nitrous Oxide for Treatment-Resistant Major Depression: A Proof-of-Concept Trial. *BMC Pharmacol. Toxicol.* 2020, 21, 12. [CrossRef] [PubMed]

148. Yang, B.; Ren, Q.; Ma, M.; Chen, Q.-X.; Hashimoto, K. Antidepressant Effects of (+)-MK-801 and (-)-MK-801 in the Social Defeat Stress Model. *Int. J. Neuropsychopharmacol.* 2016, 19, pyw080. [CrossRef] [PubMed]

149. Neis, V.B.; Moretti, M.; Rosa, P.B.; de Oliveira Dal'senter, Y.; Berle, I.; Platt, N.; Kaufmann, F.N.; Rosado, A.F.; Besen, M.H.; Rodrigues, A.L.S. The involvement of PI3K/Akt/mTOR/GSK3β signaling pathways in the antidepressant-like effect of AZD6765. *Pharmacol. Biochem. Behav.* 2020, 198, 173020. [CrossRef] [PubMed]

150. Zulian, P.; Bagewadi, H.; Banerjee, B.D.; Bhattacharya, S.K.; Mediratta, P.K. Attenuation of oxidative stress and neurotoxicity involved in the antidepressant-like effect of the MK-801(dizocilpine) in Bacillus Calmette-Guerin-induced depression in mice. *J. Basic Clin. Physiol. Pharmacol.* 2020, 31, 20190016. [CrossRef]

151. Yellepeddi, V.K.; Zhudeva, M.Y.; Movahedi, F.; Vo, A.; Phan, J.; Kirsh, R.D.; Rawlins, D.B.; Talbot, J.N. Biopharmaceutical Characterization and Oral Efficacy of a New Rapid Acting Antidepressant Ro 25-6981. *J. Pharm. Sci.* 2018, 107, 2472–2478. [CrossRef]

152. Mayer, M.L.; Armstrong, N. Structure and function of glutamate receptor ion channels. *Annu. Rev. Physiol.* 2004, 66, 161–181. [CrossRef] [PubMed]

153. Tu, W.; Xu, X.; Feng, L.; Zhong, X.; Zhang, W.; Soundarapandian, M.M.; Bølø, C.; Wang, M.; Jia, N.; Zhang, W.; et al. DAPK1 interaction with NMDA receptor NR2B subunits mediates brain damage in stroke. *Cell* 2010, 140, 222–234. [CrossRef]

154. Li, S.X.; Han, Y.; Xu, L.Z.; Yuan, K.; Zhang, R.X.; Sun, C.Y.; Xu, D.F.; Yuan, M.; Deng, J.H.; Meng, S.Q.; et al. Uncoupling DAPK1 from NMDA receptor GluN2B subunit exerts rapid antidepressant-like effects. *Mol. Psychiatry* 2018, 23, 597–608. [CrossRef]
178. Quiroz, J.A.; Tamburri, P.; Deptula, D.; Banken, L.; Beyer, U.; Rabbia, M.; Parka, N.; Fontoura, P.; Santarelli, L. Efficacy and Safety of Basinglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial. *JAMA Psychiatry* 2016, 73, 675–684. [CrossRef]

179. Liu, J.; Han, Y.-S.; Liu, L.; Tang, L.; Yang, H.; Meng, P.; Zhao, H.-Q.; Wang, Y.-H. Abnormal Glu/mGluR2/3/PI3K pathway in the hippocampal neurovascular unit leads to diabetes-related depression. *Neural Regen. Res.* 2020, 16, 727–733. [CrossRef]

180. Joffe, M.E.; Santiago, C.I.; Oliver, K.H.; Maksymetz, J.; Harris, N.A.; Lindsley, C.W.; Winder, D.G.; Conn, P.J. mGlu2 and mGlu3 negative allosteric modulators divergently potentiate thalamocortical transmission and exert rapid antidepressant-like effects. *Neuron* 2020, 105, 46–59.e43. [CrossRef]

181. Paluch-Corniewiera, A.; Pofkowa, K.; Rafoła-Ulińska, A. The group II mGlur receptor antagonist LY341495 induces a rapid antidepressant-like effect and enhances the effect of ketamine in the chronic unpredictable mild stress model of depression in C57BL/6j mice. *Prog. Neuro-Psychopharmacol. Biol. Psychiatry* 2021, 109, 110239. [CrossRef]

182. Witkin, J.M.; Mitchell, S.N.; Wafford, K.A.; Carter, G.; Gilmour, G.; Li, J.; Eastwood, B.J.; Overshiner, C.; Li, X.; Rorick-Kehn, L.; et al. Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlur) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive N-Methyl-D-Aspartate Receptor Antagonist in Rodents: Evidence Supporting the Use of mGlu2/3 Antagonists, for the Treatment of Depression. *J. Pharmacol. Exp. Ther.* 2017, 361, 68–86. [CrossRef]

183. Zanos, P.; Highland, J.N.; Stewart, B.W.; Georgiou, P.; Jenne, C.E.; Lovett, J.; Morris, P.; Thomas, C.; Moaddel, R.; Zarate, C.A.; et al. (2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions. *Proc. Natl. Acad. Sci. USA* 2019, 116, 6441–6450. [CrossRef]

184. Bartfai, T.; Lu, X.; Badie-Mahdavi, H.; Barr, A.M.; Mazarati, A.; Hua, X.-Y.; Yaksh, T.; Haberhauer, G.; Ceide, S.C.; Trembleau, L.; et al. Galanin, a nonpeptide galanin receptor agonist, affects behaviors in seizure, pain, and forced-swim tests. *Proc. Natl. Acad. Sci. USA* 2004, 101, 10470–10475. [CrossRef] [PubMed]

185. Kuteeva, E.; Hökfelt, T.; Wardi, T.; Ögren, S.O. Galanin—25 years with a multitalented neuropeptide. *Cell. Mol. Life Sci.* 2008, 65, 1854–1863. [CrossRef] [PubMed]

186. Morais, J.S.; Souza, M.M.; Campanha, T.M.N.; Muller, C.J.T.; Bittencourt, A.S.; Bortoli, V.C.; Schenber, L.C.; Beijamini, V. Galanin subtype 1 and subtype 2 receptors mediate opposite anxiety-like effects in the rat dorsal raphe nucleus. *Neur. Brain Res.* 2016, 314, 125–133. [CrossRef] [PubMed]

187. Millön, C.; Flores-Burgess, A.; Narváez, M.; Borroto-Escuela, D.O.; Santín, L.; Parrado, C.; Narváez, J.A.; Fuxe, K.; Díaz-Cabiale, Z. A Role for Galanin N-Terminal Fragment (1–15) in Anxiety- and Depression-Related Behaviors in Rats. *Int. J. Neuropsychopharmacol.* 2015, 18, pyu064. [CrossRef] [PubMed]

188. Millön, C.; Flores-Burgess, A.; Narváez, M.; Borroto-Escuela, D.O.; Santín, L.; Gago, B.; Narváez, J.A.; Fuxe, K.; Díaz-Cabiale, Z. Galanin (1-15) enhances the antidepressive effects of the 5-HT1A receptor agonist 8-OH-DPAT: Involvement of the raphe-hippocampal 5-HT neuron system. *Brain Struct. Funct.* 2020, 230, 26–30. [CrossRef] [PubMed]

189. Flores-Burgess, A.; Millón, C.; Gago, B.; Narváez, M.; Borroto-Escuela, D.O.; Mengod, G.; Narváez, J.A.; Fuxe, K.; Santín, L.; Díaz-Cabiale, Z. Galanin (1–15) enhancement of the behavioral effects of Fluoxetine in the forced swimming test gives a new therapeutic strategy against depression. *Neuropharmacology* 2017, 118, 233–241. [CrossRef]

190. Flores-Burgess, A.; Millón, C.; Gago, B.; García-Durán, L.; Cantero-García, N.; Covenas, R.; Narváez, J.A.; Fuxe, K.; Santín, L.; Díaz-Cabiale, Z. Galanin (1–15)-fluoxetine interaction in the novel object recognition test. Involvement of 5-HT1A receptors in the prefrontal cortex of the rats. *Neuropharmacology* 2019, 155, 104–112. [CrossRef]

191. Funck, V.R.; Fracalossi, M.P.; Vidigal, A.P.P.; Beijamini, V. Dorsal hippocampal galanin modulates anxiety-like behaviours in rats. *Brain Res.* 2018, 1687, 74–81. [CrossRef]

192. de Souza, M.M.; Silote, G.P.; Herbst, L.S.; Funck, V.R.; Joca, S.R.L.; Beijamini, V. The antidepressant-like effect of galanin in the dorsal raphe nucleus of rats involves GAL1 receptors. *Neurosci. Lett.* 2018, 681, 26–30. [CrossRef]

193. Saar, I.; Lahe, J.; Langel, K.; Runesson, J.; Webling, K.; Järv, J.; Rytkönen, J.; Närävänä, A.; Bartfai, T.; Kurkkiok, K.; et al. Novel systemically active galanin receptor 2 ligands in depression-like behavior. *J. Neurochem.* 2013, 127, 114–123. [CrossRef]

194. Adzic, M.; Brkic, Z.; Mitic, M.; Franciæ, J.; Jovicæ, M.J.; Rudulovic, J.; Marie, N.P. Therapeutic Strategies for Treatment of Inflammation-related Depression. *Curr. Neuropharmacol.* 2018, 16, 176–209. [CrossRef] [PubMed]

195. Dowlati, Y.; Herrmann, N.; Swardfager, W.; Liu, H.; Sham, L.; Reim, E.K.; Lancot, K.L. A meta-analysis of cytokines in major depression. *Biol. Psychiatry* 2010, 67, 446–457. [CrossRef] [PubMed]

196. Liu, Y.; Ho, R.C.-M.; Mak, A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: A meta-analysis and meta-regression. *J. Affect. Disord.* 2012, 139, 230–239. [CrossRef] [PubMed]

197. Howren, M.B.; Lamkin, D.M.; Suls, J. Associations of depression with C-reactive protein, IL-1, and IL-6: A meta-analysis. *Psychosom. Med.* 2009, 71, 171–186. [CrossRef]

198. Benros, M.E.; Waftko, B.L.; Nordentoft, M.; Ostergard, S.D.; Eaton, W.W.; Krogh, J.; Mortensen, P.B. Autoimmune diseases and severe infections as risk factors for mood disorders: A nationwide study. *JAMA Psychiatry* 2013, 70, 812–820. [CrossRef]

199. Reichenberg, A.; Gorman, J.M.; Dieterich, D.T. Interferon-induced depression and cognitive impairment in hepatitis C virus patients: A 72 week prospective study. *Aids* 2005, 19 (Suppl. 3), S174–S178. [CrossRef]
200. Müller, N.; Schwarz, M.J.; Dehning, S.; Douhe, A.; Ceverecki, A.; Goldstein-Müller, B.; Spellmann, I.; Hetzel, G.; Maino, K.; Kleindienst, N.; et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: Results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. *Mol. Psychiatry* **2006**, *11*, 680–684. [CrossRef]

201. Sokol, C.L.; Luster, A.D. The chemokine system in innate immunity. *Cold Spring Harb. Perspect. Biol.* **2015**, *7*, a016303. [CrossRef]

202. Piper, P.; Vane, J. The release of prostaglandins from lung and other tissues. *Ann. N. Y. Acad. Sci.* **1971**, *180*, 363–385. [CrossRef]

203. Morgan, A.; Kondev, V.; Bedse, G.; Baldi, R.; Marcus, D.; Patel, S. Cyclooxygenase-2 inhibition reduces anxiety-like behavior and normalizes enhanced amygdala glutamatergic transmission following chronic oral corticosteroid treatment. *Neurobiol. Stress* **2019**, *11*, 100190. [CrossRef]

204. Luo, W.; Luo, Y.; Yang, J. Proteomics-based screening of the target proteins associated with antidepressant-like effect and mechanism of nimesulide. *Sci. Rep.* **2020**, *10*, 11052. [CrossRef] [PubMed]

205. Jafarinia, M.; Afarineh, M.; Tafakhor, A.; Arbabi, M.; Ghajar, A.; Noorbala, A.A.; Saravi, M.A.; Agah, E.; Akhoundzadeh, S. Efficacy and safety of oral ketanserin versus diclofenac to alleviate mild to moderate depression in cancer patients: A double-blind, randomized, controlled trial. *J. Affect. Disord.* **2016**, *204*, 1–8. [CrossRef] [PubMed]

206. Majd, M.; Hashemian, F.; Hosseini, S.M.; Vahdat Shariatpanahi, M.; Sharifi, A. A Randomized, Double-blind, Placebo-controlled Trial of Celecoxib Augmentation of Sertraline in Treatment of Drug-naive Depressed Women: A Pilot Study. *Iran. J. Pharm. Res. IJPR* **2015**, *14*, 891–899. [PubMed]

207. Fourrier, C.; Sampson, E.; Mills, N.T.; Baune, B.T. Anti-inflammatory treatment of depression: Study protocol for a randomised controlled trial of vortioxetine versus celecoxib or placebo. *Trials* **2018**, *19*, 447. [CrossRef] [PubMed]

208. Orlando, B.J.; Lucido, M.J.; Malkowski, M.G. The Structure of Ibuprofen Bound To Cyclooxygenase-2. *J. Struct. Biol.* **2015**, *189*, 62–66. [CrossRef]

209. Mesripour, A.; Shahnoshi, S.; Hajhashemi, V. Celecoxib, ibuprofen, and indomethacin alleviate depression-like behavior induced by interferon-α in mice. *J. Complementary Integr. Med.* **2020**, *17*, 16. [CrossRef]

210. Nozari, M.; Nahavandi, A.; Zeinivand, M.; Eslami Gharaati, M.; Godarzi, M.; Ahmadi, M.; Jamali-Raeufy, N. Ibuprofen Protection Against Restrained Chronic Stress-induced Depression in Male Rats. *Basic Clin. Neurosci.* **2020**, *11*, 413–422. [CrossRef]

211. Seo, M.K.; Lee, J.G.; Park, S.W. Effects of escitalopram and ibuprofen on a depression-like phenotype induced by chronic stress in rats. *Neurosci. Lett.* **2019**, *696*, 168–173. [CrossRef]

212. Savitz, J.B.; Teague, T.K.; Misaki, M.; Macaluso, M.; Wurfel, B.E.; Meyer, D.; Drevets, W.C.; et al. Treatment of bipolar depression with minocycline and/or aspirin: An adaptive, 2 × 2 double-blind, randomized, placebo-controlled, phase IIa clinical trial. *Transl. Psychiatry* **2018**, *8*, 27. [CrossRef]

213. Angiolillo, D.J.; Weisman, S.M. Clinical Pharmacology and Cardiovascular Safety of Naproxen. *Am. J. Cardiovasc. Drugs* **2017**, *17*, 97–107. [CrossRef]

214. Iyengar, R.L.; Gandhi, S.; Aneja, A.; Thorpe, K.; Razzouk, L.; Greenberg, J.; Mosovich, S.; Farkouh, M.E. NSAIDs Are Associated with Lower Depression Scores in Patients with Osteoarthritis. *Am. J. Med.* **2013**, *126*, 1017.e1011–1017.e1018. [CrossRef] [PubMed]

215. Fields, C.; Drye, L.; Vaidya, V.; Lyketsos, C. Celecoxib or naproxen treatment does not benefit depressive symptoms in persons aged 70 and over: Findings from a randomized controlled trial. *Am. J. Geriatr. Psychiatry* **2012**, *20*, 505–513. [CrossRef] [PubMed]

216. Berk, M.; Woods, R.L.; Nelson, M.R.; Shah, R.C.; Reid, C.M.; Storey, E.; Fitzgerald, S.; Lockery, J.E.; Wolfe, R.; Mohebbi, M.; et al. Effect of Aspirin vs. Placebo on the Prevention of Depression in Older People. *JAMA Psychiatry* **2020**, *77*, 1012–1020. [CrossRef] [PubMed]

217. Tyring, S.; Gottlieb, A.; Papp, K.; Gordon, K.; Leonardi, C.; Wang, A.; Lalla, D.; Woolley, M.; Jahreis, A.; Zitnik, R.; et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo-controlled randomised phase III trial. *Lancet* **2006**, *367*, 29–35. [CrossRef]

218. Mansur, R.B.; Delgado-Peraza, F.; Subramaniapillai, M.; Lee, Y.; Iacobucci, M.; Rodrigues, N.; Rosenblat, J.D.; Bietzke, E.; Cosgrove, V.E.; Kramer, N.E.; et al. Extracellular Vesicle Biomarkers Reveal Inhibition of Neuroinflammation by Infliximab in Association with Antidepressant Response in Adults with Osteoarthritis. *Cells* **2020**, *9*, 895. [CrossRef]

219. Murrough, J.W.; Hurky, K.M.; Yao, X.; Iacoviello, B.; Collins, K.; Nierenberg, A.A.; Kang, G.; Shungu, D.C.; Iosifescu, D.V. A pilot study of minocycline for the treatment of bipolar depression: Effects on cortical glutathione and oxidative stress in vivo. *J. Affect. Disord.* **2018**, *230*, 56–64. [CrossRef]

220. Zazula, R.; Husain, M.I.; Mohebbi, M.; Walker, A.J.; Chaudhry, I.B.; Khosob, A.B.; Ashton, M.M.; Agustini, B.; Husain, N.; Deakin, J.F.W.; et al. Minocycline as adjunctive treatment for major depressive disorder: Pooled data from two randomized controlled trials. *Aust. N. Z. J. Psychiatry* **2021**, *55*, 784–798. [CrossRef]

221. Nettis, M.A.; Lombardo, G.; Hastings, C.; Zajkowska, Z.; Mariani, N.; Nikkheslat, N.; Worrell, C.; Enache, D.; McLaughlin, A.; Kose, M.; et al. Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: Results from a double-blind randomised clinical trial. *Neuropsychopharmacology* **2021**, *46*, 939–948. [CrossRef]

222. Reich, K.; Foley, P.; Han, C.; McElligott, S.; Muser, E.; Li, N.; Armstrong, A.W. Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: Results from the VOYAGE 2 comparator study versus adalimumab. *J. Dermatol. Treat.* **2020**, *31*, 617–623. [CrossRef]
223. Kim, S.-J.; Park, M.-Y.; Pak, K.; Han, J.; Kim, G.-W.; Kim, H.-S.; Ko, H.-C.; Kim, M.-B.; Kim, B.-S. Improvement of depressive symptoms in patients with moderate-to-severe psoriasis treated with ustekinumab: An open label trial validated using beck depression inventory; Hamilton depression rating scale measures and 18fluorodeoxyglucose (FDG) positron emission tomography (PET). J. Dermatol. Treat. 2018, 29, 761–768. [CrossRef]

224. Brymer, K.J.; Fenton, E.Y.; Kalyuzhny, L.E.; Caruncho, H.J. Peripheral Etanercept Administration Normalizes Behavior, Hippocampal Neurogenesis, and Hippocampal Reelin and GABAA Receptor Expression in a Preclinical Model of Depression. Front. Pharmacol. 2018, 9, 121. [CrossRef] [PubMed]

225. Tiosano, S.; Yavne, Y.; Watad, A.; Langervitz, P.; Lidar, M.; Feld, J.; Tisher, M.; Aamar, S.; Elkayam, O.; Balbir-Gurman, A.; et al. The impact of tocilizumab on anxiety and depression in patients with rheumatoid arthritis. Eur. J. Clin. Invest. 2020, 50, e13268. [CrossRef]

226. Scheinfeld, N.; Sundaram, M.; Teixeira, H.; Gu, Y.; Okun, M. Reduction in pain scores and improvement in depressive symptoms in patients with hidradenitis suppurativa treated with adalimumab in a phase 2, randomized, placebo-controlled trial. Dermatol. Online J. 2016, 22, 2. [CrossRef]

227. Chakraborty, S.; Tripathi, S.; Raju, T.R.; Shankaranarayana Rao, B.S. Mechanisms underlying remediation of depression-associated anxiety by chronic N-acetyl cysteine treatment. Psychopharmacology 2020, 237, 2967–2981. [CrossRef] [PubMed]

228. Fan, C.; Long, Y.; Wang, L.; Liu, X.; Liu, Z.; Lan, T.; Li, Y.; Yu, S.Y. N-Acetylcysteine Rescues Hippocampal Oxidative Stress-Induced Neuronal Injury via Suppression of p38/JNK Signaling in Depressed Rats. Front. Cell. Neurosci. 2020, 14, 554613. [CrossRef] [PubMed]

229. Han, J.; Chen, D.; Liu, D.; Zhu, Y. Modafinil attenuates inflammation via inhibiting Akt/NF-κB pathway in apoE-deficient mouse model of atherosclerosis. Inflammopharmacology 2018, 26, 385–393. [CrossRef]

230. Beurel, E.; Toups, M.; Nemeroff, C.B. The Bidirectional Relationship of Depression and Inflammation: Double Trouble. Neuropsychopharmacology 2013, 38, 234–256. [CrossRef]

231. Kohler, O.; Krogh, J.; Mors, O.; Benros, M.E. Inflammation in Depression and the Potential for Anti-Inflammatory Treatment. Curr. Neuropharmacol. 2016, 14, 732–742. [CrossRef]

232. Lotrich, F.E. Inflammatory cytokine-associated depression. Brain Res. 2015, 1617, 113–125. [CrossRef]

233. Keller, J.; Gomez, R.; Williams, G.; Lembke, A.; Lazzeroni, L.; Murphy, G.M.; Schatzberg, A.F. HPA Axis in Major Depression: A Crucial Role of the Mineralocorticoid Receptor. J. Neuroendocrinol. 2016, 28, 22. [CrossRef]

234. Laryea, G.; Schütz, G.; Muglia, L.J. Disrupting hypothalamic glucocorticoid receptors causes HPA axis hyperactivity and excess adiposity. Mol. Endocrinol. 2013, 27, 1655–1665. [CrossRef] [PubMed]

235. Menke, A. Is the HPA Axis As Target for Depression Outdated, or Is There a New Hope? Front. Psychiatry 2019, 10, 101. [CrossRef] [PubMed]

236. Wagner, S.; Doering, B.; Helmreich, I.; Lieb, K.; Tadić, A. A meta-analysis of executive dysfunctions in unipolar major depression disorder without psychotic symptoms and their changes during antidepressant treatment. Acta Psychiatr. Scand. 2012, 125, 281–292. [CrossRef] [PubMed]

237. Bogdan, R.; Williamson, D.E.; Hariri, A.R. Mineralocorticoid Receptor Iso/Val (rs5522) Genotype Moderates the Association Between Previous Childhood Emotional Neglect and Amygdala Reactivity. Am. J. Psychiatry 2012, 169, 515–522. [CrossRef]

238. Vinkers, C.H.; Joëls, M.; Milaneschi, Y.; Gerritsen, L.; Kahn, R.S.; Penninx, B.W.J.H.; Boks, M.P.M. Mineralocorticoid receptor haplotypes sex-dependently moderate depression susceptibility following childhood maltreatment. Psychoneuroendocrinology 2015, 54, 90–102. [CrossRef]

239. Joëls, M.; Kloet, E.R.D. 30 years of the mineralocorticoid receptor: The brain mineralocorticoid receptor: A saga in three episodes. J. Endocrinol. 2017, 234, T49–T66. [CrossRef] [PubMed]

240. de Kloet, E.R.; Otte, C.; Kumsta, R.; Kok, L.; Hillegers, M.H.J.; Hasselmann, H.; Kliegl, D.; Joëls, M. Stress and Depression: A Crucial Role of the Mineralocorticoid Receptor. J. Neuroendocrinol. 2016, 28. [CrossRef]

241. Otte, C.; Wingenfeld, K.; Kuehl, L.K.; Kazcmarczyk, M.; Richter, S.; Quante, A.; Regen, F.; Bajbouj, M.; Zimmermann-Viehoff, F.; Wiedemann, K.; et al. Mineralocorticoid Receptor Stimulation Improves Cognitive Function and Decreases Cortisol Secretion in Depressed Patients and Healthy Individuals. Neuropsychopharmacology 2015, 40, 386–393. [CrossRef]

242. Vogel, S.; Klumpers, L.; Thörner, T.N.; Oplaat, K.T.; Krugers, H.J.; Oitzl, M.S.; Joëls, M.; Doeller, C.F.; Fernández, G. Stress Induces a Shift towards Striatum-Dependent Stimulus-Response Learning via the Mineralocorticoid Receptor. Neuropsychopharmacology 2017, 42, 1262–1271. [CrossRef]

243. Juruena, M.F.; Pariante, C.M.; Papadopoulos, A.S.; Poon, L.; Lightman, S.; Cleare, A.J. The role of mineralocorticoid receptor function in treatment-resistant depression. J. Psychopharmacol. 2013, 27, 1169–1179. [CrossRef]

244. Tyan, R.J.; Beynon, S.B.; Hinwood, M.; Johnson, S.J.; Nilsson, M.; Woods, J.J.; Walker, F.R. Chronic stress-induced disruption of the astrocyte network is driven by structural atrophy and not loss of astrocytes. Acta Neuropathol. 2013, 126, 75–91. [CrossRef] [PubMed]

245. Lee, C.-H.; Giuliani, F. The Role of Inflammation in Depression and Fatigue. Front. Immunol. 2019, 10, 1696. [CrossRef] [PubMed]

246. Gomez-Sanchez, E.; Gomez-Sanchez, C.E. The Multifaceted Mineralocorticoid Receptor. Compr. Physiol. 2014, 4, 965–994. [CrossRef] [PubMed]

247. Oakley, R.H.; Cidlowski, J.A. The Biology of the Glucocorticoid Receptor: New Signaling Mechanisms in Health and Disease. J. Allergy Clin. Immunol. 2013, 132, 1033–1044. [CrossRef]

248. Pariante, C.M.; Miller, A.H. Glucocorticoid receptors in major depression: Relevance to pathophysiology and treatment. Biol. Psychiatry 2001, 49, 391–404. [CrossRef]
249. Lotan, A.; Lifschytz, T.; Merrick, B.; Lory, O.; Levi, E.; Ben-Shimol, E.; Goelman, G.; Lerer, B. Alterations in the expression of a neurodevelopmental gene exert long-lasting effects on cognitive-emotional phenotypes and functional brain networks: Translational evidence from the stress-resilient Ahil knockout mouse. *Mol. Psychiatry* 2017, 22, 884–889. [CrossRef]

250. Xu, X.; Yang, H.; Lin, Y.-F.; Li, X.; Cape, A.; Ressler, K.J.; Li, S.; Li, X.-J. Neuronal Abelsern helpier integration site-1 (Ahi1) deficiency in mice alters TrkB signaling with a depressive phenotype. *Proc. Natl. Acad. Sci. USA* 2010, 107, 19126–19131. [CrossRef]

251. Wang, B.; Xin, N.; Qian, X.; Zhai, L.; Miao, Z.; Yang, Y.; Li, S.; Sun, M.; Xu, X.; Li, X.-J. Ahi1 regulates the nuclear translocation of glucocorticoid receptor to modulate stress response. *Trans. Psychiatry* 2021, 11, 188. [CrossRef]

252. Menke, A.; Klengel, T.; Rubel, J.; Brückl, T.; Pfister, H.; Lucaes, S.; Uhr, M.; Holsboer, F.; Binder, E.B. Genetic variation in FKBP5 associated with the extent of stress hormone dysregulation in major depression. *Genes Brain Behav.* 2013, 12, 289–296. [CrossRef]

253. Kwon, J.; Kim, Y.J.; Choi, K.; Seol, S.; Kang, H.J. Identification of stress resilience module by weighted gene co-expression network analysis in Fkbp5-deficient mice. *Mol. Brain* 2019, 12, 99. [CrossRef]

254. Ridder, S.; Chourbaji, S.; Hellweg, R.; Urami, A.; Zacher, S.; Schmid, W.; Zink, M.; Hörtnagl, H.; Flor, H.; Henn, F.A.; et al. Mice with Genetically Altered Glucocorticoid Receptor Expression Show Altered Sensitivity for Stress-Induced Depressive Reactions. *J. Neurosci.* 2005, 25, 6243–6250. [CrossRef] [PubMed]

255. George, S.A.; Rodríguez-Santiago, M.; Riley, J.; Rodriguez, E.; Liberzon, I. The effect of chronic phenytoin administration on the opioid system in the antidepressant-like effect of simvastatin in mice: Without tolerance and withdrawal syndrome. *Int. Immunopharmacol.* 2019, 939–949. [CrossRef] [PubMed]

256. Kamiya, M.; Sabia, H.D.; Marella, J.; Fava, M.; Nemeroff, C.B.; Umeuchi, H.; Iijima, M.; Chaki, S.; Nishino, I. Efficacy and safety of the mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitary-adrenal activity in humans with psychotic major depression. *Psychoneuroendocrinology* 2013, 38, 115–121. [CrossRef] [PubMed]

257. Belanoff, J.K.; Kaledzhian, M.; Sund, B.; Fleming Ficek, S.K.; Schatzberg, A.F. Cortisol activity and cognitive changes in psychotic major depression. *Am. J. Psychiatry* 2001, 158, 1612–1616. [CrossRef]

258. Block, T.S.; Kushner, H.; Kalin, N.; Nelson, C.; Belanoff, J.; Schatzberg, A. Combined Analysis of Mifepristone for Psychotic Major Depression: Plasma Levels Associated with Clinical Response. *Biol. Psychiatry* 2018, 84, 46–54. [CrossRef]

259. Donoghue, K.; Rose, A.; Coulton, S.; Coleman, R.; Milward, J.; Philips, T.; Drummond, C.; Little, H. Double-blind, placebo-controlled trial of mifepristone on cognition and depression in alcohol dependent. *Trials* 2020, 21, 796. [CrossRef]

260. Katz, D.A.; Locke, C.; Greco, N.; Liu, W.; Tracy, K.A. Hypothalamic-pituitary-adrenal axis and depression symptom effects of an arginine vasopressin type 1B receptor antagonist in a one-week randomized Phase 1b trial. *Brain Behav.* 2017, 7, e00628. [CrossRef]

261. Kamiya, M.; Sabia, H.D.; Marella, J.; Fava, M.; Nemeroff, C.B.; Umeuchi, H.; Iijima, M.; Chaki, S.; Nishino, I. Efficacy and safety of TS-121, a novel vasopressin V1B receptor antagonist, as adjunctive treatment for patients with major depressive disorder: A randomized, double-blind, placebo-controlled study. *J. Psychiatr. Res.* 2020, 128, 43–51. [CrossRef]

262. National Clinical Guideline Centre (UK). Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lids for the Primary and Secondary Prevention of Cardiovascular Disease; National Institute for Health and Care Excellence: London, UK, 2014.

263. Macin, S.M.; Perna, E.R.; Faram, E.F.; Franciosi, V.; Cialzeta, J.R.; Brizuela, M.; Medina, F.; Tajer, C.; Doval, H.; Badaracco, R. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: Results of a randomized, double-blind, placebo-controlled study. *Am. Heart J.* 2005, 149, 451–457. [CrossRef]

264. Yu, X.-B.; Zhang, H.-N.; Dai, Y.; Zhou, Z.-Y.; Xu, R.-A.; Hu, L.-F.; Zhang, C.-H.; Hu, H.-Q.; An, Y.-Q.; Tang, C.-R.; et al. Simvastatin prevents and ameliorates depressive behaviors via neuroinflammatory regulation in mice. *J. Affect. Disord.* 2019, 245, 939–949. [CrossRef] [PubMed]

265. Wu, H.; Lv, W.; Fan, Q.; Kalavagunta, P.K.; Liu, Q.; Qin, G.; Cai, M.; Zhou, L.; Wang, T.; Xia, Z.; et al. Simvastatin therapy in adolescent mice attenuates HFD-induced depression-like behavior by reducing hippocampal neuroinflammation. *J. Affect. Disord.* 2019, 243, 83–95. [CrossRef] [PubMed]

266. Menze, E.T.; Ezzat, H.; Shawky, S.; Sami, M.; Selim, E.H.; Ahmed, S.; Maged, N.; Nadeem, N.; Eldash, S.; Michel, H.E. Simvastatin mitigates depressive-like behavior in ovariectomized rats: Possible role of NLRP3 inflammasome and estrogen receptors’ modulation. *Int. Immunopharmacol.* 2021, 95, 107582. [CrossRef]

267. Dolatshahi, M.; Davoudi, S.; Paridar, Y.; Naserzadeh, R.; Ghorbanzadeh, B. Pharmacological evidence for the involvement of the opioid system in the antidepressant-like effect of simvastatin in mice: Without tolerance and withdrawal syndrome. *Neurosci. Lett.* 2020, 714, 134578. [CrossRef]

268. Taniguti, E.H.; Ferreira, Y.S.; Stupp, I.J.V.; Fraga-Junior, E.B.; Doneda, D.L.; Lopes, L.; Rios-Santos, F.; Lima, E.; Buss, Z.S.; Viola, G.G.; et al. Atorvastatin prevents lipopolysaccharide-induced depressive-like behaviour in mice. *Brain Res. Bull.* 2019, 146, 279–286. [CrossRef] [PubMed]

269. Hai-Na, Z.; Xu-Ben, Y.; Cong-Rong, T.; Yan-Cheng, C.; Fan, Y.; Lei-Mei, X.; Ruo-Lan, S.; Ye-Zi, n.; Ye-Xuan, W.; Jing, L. Atorvastatin ameliorates depressive behaviors and neuroinflammation in streptozotocin-induced diabetic mice. *Psychopharmacology* 2020, 237, 695–705. [CrossRef]
271. Yan, J.; Huang, J.; Liu, A.; Wu, J.; Fan, H.; Shen, M.; Lai, X.; Ma, H.; Sun, W.; Yang, J.; et al. Atorvastatin improves motor function, anxiety and depression by NOX2-mediated autophagy and oxidative stress in MPTP-lesioned mice. *Aging* 2020, 13, 831–845. [CrossRef]

272. Rahangdile, S.; Fating, R.; Gajbiye, M.; Kapse, M.; Inamdar, N.; Kotagale, N.; Umekar, M.; Taksande, B. Involvement of agmatine in antidepressant-like effect of HMG-CoA reductase inhibitors in mice. *Eur. J. Pharmacol.* 2021, 892, 173739. [CrossRef] [PubMed]

273. Tang, C.-R.; Yu, X.-B.; Zhang, H.-N.; Cao, Y.-C.; Yang, F.; Xu, L.-M.; Sun, R.-L.; Ye, Z.; Wang, Y.-X.; Liang, J. Lovastatin Prevents Depressive Behaviors and Increased Hippocampal Neurogenesis in Streptozotocin-Induced Diabetic Mice. *Pharmacology 2020*, 105, 339–348. [CrossRef]

274. Hu, M.; Cheung, B.M.Y.; Tomlinson, B. Safety of statins: An update. *Ther. Adv. Drug Saf.* 2012, 3, 133–144. [CrossRef]

275. Milner, R.J.; Farese, J.; Henry, C.J.; Selting, K.; Fan, T.M.; de Lorimier, L.P. Bisphosphonates and cancer. [CrossRef]

276. Romijn, A.R.; Rucklidge, J.J.; Kuijer, R.G.; Frampton, C. A double-blind, randomized, placebo-controlled trial of Lactobacillus

277. Chung, Y.-C.; Jin, H.-M.; Cui, Y.; Kim, D.S.; Jung, J.M.; Park, J.-I.; Jung, E.-S.; Choi, E.-K.; Chae, S.-W. Fermented milk of Lactobacillus

278. Allen, A.P.; Hutch, W.; Borre, Y.E.; Kennedy, P.J.; Temko, A.; Boylan, G.; Murphy, E.; Cryan, J.F.; Dinan, T.G.; Clarke, G. Bifidobacterium longum 1714 as a translational psychobiotic: Modulation of stress, electrophysiology and neurocognition in healthy volunteers. *Brain Behav. Immun.* 2016, 565–573. [CrossRef] [PubMed]

279. Wang, S.; Ishima, T.; Zhang, J.; Qu, Y.; Chang, L.; Pu, Y.; Fujita, Y.; Tan, Y.; Wang, X.; Hashimoto, K. Ingestion of Lactobacillus intestinales and Lactobacillus reuteri causes depression- and anhedonia-like phenotypes in antibiotic-treated mice via the vagus nerve. *Neuroinflammation* 2020, 17, 241. [CrossRef] [PubMed]

280. Wang, S.; Ishima, T.; Qu, Y.; Shan; J.; Chang, L.; Wei, Y.; Zhang, J.; Pu, Y.; Fujita, Y.; Tan, Y.; et al. Ingestion of Faecalibaculum rodentium causes depression-like phenotypes in resilient Ephx2 knockout-out mice: A role of brain–gut-microbiota axis via the subdiaphragmatic vagus nerve. *J. Affect. Disord.* 2021, 292, 565–573. [CrossRef] [PubMed]

281. Wang, S.; Qu, Y.; Chang, L.; Pu, Y.; Zhang, K.; Hashimoto, K. Antibiotic-induced microbiome depletion is associated with resilience in mice after chronic social defeat stress. *J. Affect. Disord.* 2020, 260, 448–457. [CrossRef]

282. Kosuge, A.; Kunisawa, K.; Arai, S.; Sugawara, Y.; Shinohara, K.; Iida, T.; Wulaer, B.; Fujigaki, H.; Yamamoto, Y.; et al. Heat-sterilized Bifidobacterium breve prevents depression-like behavior and interleukin-1β expression in mice exposed to chronic social defeat stress. *Brain Behav. Immun.* 2021, 96, 200–211. [CrossRef]

283. Burokas, A.; Arborela, S.; Moloney, R.D.; Peterson, V.L.; Murphy, K.; Clarke, G.; Stanton, C.; Dinan, T.G.; Cryan, J.F. Targeting the Microbiota-Gut-Brain Axis: Prebiotics Have Anxiolytic and Antidepressant-like Effects and Reverse the Impact of Chronic Stress in Mice. *Biol. Psychiatry* 2017, 82, 472–487. [CrossRef]

284. Yang, C.; Fujita, Y.; Ren, Q.; Ma, M.; Dong, C.; Hashimoto, K. Bifidobacterium in the gut microbiota confer resilience to chronic social defeat stress in mice. *Sci. Rep.* 2017, 7, 45942. [CrossRef]

285. Burokas, A.; Esmaillzadeh, A. Clinical and metabolic response to probiotic administration in patients with major depressive disorder: A pilot study. *J. Affect. Disord.* 2016, 171, 200–211. [CrossRef]

286. Burokas, A.; Arborela, S.; Moloney, R.D.; Peterson, V.L.; Murphy, K.; Clarke, G.; Stanton, C.; Dinan, T.G.; Cryan, J.F. Targeting the Microbiota-Gut-Brain Axis: Prebiotics Have Anxiolytic and Antidepressant-like Effects and Reverse the Impact of Chronic Stress in Mice. *Biol. Psychiatry* 2017, 82, 472–487. [CrossRef] [PubMed]

287. Ng, Q.X.; Peters, C.; Ho, C.Y.X.; Lim, D.Y.; Yeo, W.-S. A meta-analysis of the use of probiotics to alleviate depressive symptoms. [CrossRef] [PubMed]

288. Pinto-Sanchez, M.I.; Hall, G.B.; Ghajar, K.; Nardelli, A.; Bolino, C.; Lau, J.T.; Martin, F.P.; Cominotti, O.; Welsh, C.; Rieder, A.; et al. Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients with Irritable Bowel Syndrome. *Gastroenterology* 2017, 153, 448–459.e448. [CrossRef] [PubMed]

289. Akkasheh, G.; Kashani-Poor, Z.; Tajabadi-Ebrahimi, M.; Jafari, P.; Akbari, H.; Taghizadeh, M.; Memarzadeh, M.R.; Asemi, Z.; Esmaillzadeh, A. Clinical and metabolic response to probiotic administration in patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial. *Nutrition* 2016, 32, 315–320. [CrossRef] [PubMed]

290. Kelly, J.R.; Allen, A.P.; Temko, A.; Hutch, W.; Kennedy, P.J.; Farid, N.; Murphy, E.; Boylan, G.; Bienenstock, J.; Cryan, J.F.; et al. Lost in translation? The potential psychobiotic Lactobacillus rhamnosus (JB-1) fails to modulate stress or cognitive performance in healthy male subjects. *Brain Behav. Immun.* 2017, 61, 50–59. [CrossRef]

291. Kazemi, A.; Noorbala, A.A.; Azam, K.; Eskandari, M.H.; Djafarian, K. Effect of probiotic and prebiotic vs. placebo on psychological outcomes in patients with major depressive disorder: A randomized clinical trial. *Clin. Nutr.* 2019, 38, 522–528. [CrossRef]

292. Eskandarzadeh, S.; Effatpanah, M.; Khosravi-Darani, K.; Askari, R.; Hosseini, A.F.; Reisian, M.; Jazayeri, S. Efficacy of a multispecies probiotic as adjunctive therapy in generalized anxiety disorder: A double blind, randomized, placebo-controlled trial. *Nutr. Neurosci.* 2021, 24, 102–108. [CrossRef]

293. Nielsen, N.D.; Sandager, M.; Stafford, G.I.; van Staden, J.; Jäger, A.K. Screening of indigenous plants from South Africa for affinity to the serotonin reuptake transport protein. *J. Ethnopharmacol.* 2004, 94, 159–163. [CrossRef]
295. Pedersen, M.E.; Szewczyk, B.; Stachowicz, K.; Wieronska, J.; Andersen, J.; Stafford, G.I.; van Staden, J.; Pilc, A.; Jäger, A.K. Effects of South African traditional medicine in animal models for depression. J. Ethnopharmacol. 2008, 119, 542–548. [CrossRef] [PubMed]

296. Han, X.H.; Hong, S.S.; Hwang, J.S.; Lee, M.K.; Hwang, B.Y.; Ro, J.S. Monoamine oxidase inhibitory components from Câyratia japonica. Arch. Pharm. Res. 2007, 30, 13–17. [CrossRef] [PubMed]

297. Butterweck, V.; Nishibe, S.; Sasaki, T.; Uchiida, M. Antidepressant effects of apocynum venetum leaves in a forced swimming test. Biol. Pharm. Bull. 2001, 24, 848–851. [CrossRef] [PubMed]

298. Zheng, M.; Fan, Y.; Shi, D.; Liu, C. Antidepressant-like effect of flavonoids extracted from Apocynum venetum leaves on brain monoamine levels and dopaminergic system. J. Ethnopharmacol. 2013, 147, 108–113. [CrossRef]

299. Moragrega, I.; Kios, J.L. Medicinal Plants in the Treatment of Depression: Evidence from Preclinical Studies. Planta Med. 2021, 87, 656–685. [CrossRef]

300. Qiao, Y.-L.; Zhou, J.-J.; Liang, J.-H.; Deng, X.-P.; Zhang, Z.-J.; Huang, H.-L.; Li, S.; Dai, S.-F.; Liu, C.-Q.; Luan, Z.-L.; et al. Uncaria rhynchophylla ameliorates unpredictable chronic mild stress-induced depression in mice via activating 5-HT1A receptor: Insights from transcriptomics. Phytotherapy 2021, 81, 153436. [CrossRef]

301. Li, R.; Wang, Z.-M.; Wang, Y.; Dong, X.; Zhang, L.-H.; Wang, T.; Zhu, Y.; Gao, X.-M.; Wu, H.-H.; Xu, Y.-T. Antidepressant activities and regulative effects on serotonin transporter of Nardostachys jatamansi DC. J. Ethnopharmacol. 2021, 265, 113681. [CrossRef]

302. Xia, B.; Huang, X.; Sun, G.; Tao, W. Iridoids from Gardeniae fructus ameliorates depression by enhancing synaptic plasticity via AMPA receptor-mTOR signaling. J. Ethnopharmacol. 2021, 268, 113665. [CrossRef]

303. Pulido-Salas, M.T. Atlas de las Plantas de la Medicina Tradicional Mexicana. Atlas of the Plants of Mexican Indigenous Medicine; Instituto Nacional Indigenista: Mexico City, Mexico, 1994.

304. Martínez-Hernández, G.B.; Jiménez-Ferrer, E.; Román-Ramos, R.; Zamilpa, A.; González-Cortazar, M.; León-Rivera, I.; Vargas-Villa, G.; Herrera-Ruiz, M. A mixture of quercetin 4’-O-rhamnoside and isoquercitrin from Tilia americana var. mexicana and its biotransformation products with antidepressant activity in mice. J. Ethnopharmacol. 2021, 267, 113619. [CrossRef]

305. Jiang, N.; Huang, H.; Wang, H.; Lv, J.; Zeng, G.; Wang, Q.; Bao, Y.; Chen, Y.; Liu, X.-M. The antidepressant-like effects of Shen Yuan: Dependence on hippocampal BDNF-TrkB signaling activation in chronic social defeat depression-like mice. Phytother. Res. 2021, 35, 2711–2726. [CrossRef]

306. Jiang, N.; Wang, H.; Huang, H.; Lv, J.; Zeng, G.; Wang, Q.; Bao, Y.; Chen, Y.; Liu, X. The Antidepressant-Like Effects of Shen Yuan in a Chronic Unpredictable Mild Stress Rat Model. Front. Psychiatry 2021, 12, 622204. [CrossRef] [PubMed]

307. Wu, L.; Zhang, T.; Chen, K.; Lu, C.; Liu, X.F.; Zhou, J.L.; Huang, Y.K.; Yan, H.; Chen, Y.; Zhang, C.J.; et al. Rapid antidepressant-like effect of Fructus Aurantii depends on cAMP-response element binding protein/Brain-derived neurotrophic factor by mediating synaptic transmission. Phytother. Res. 2021, 35, 404–414. [CrossRef] [PubMed]

308. Jiang, N.; Wang, H.; Li, C.; Zeng, G.; Gao, X.-M.; Wu, H.-H.; Xu, Y.-T.; Wang, Q.; Chen, Y.; Liu, X. The antidepressant-like effects of the water extract of Panax ginseng and Polygala tenuifolia are mediated via the BDNF-TrkB signaling pathway and neurogenesis in the hippocampus. J. Ethnopharmacol. 2021, 267, 113625. [CrossRef] [PubMed]

309. Maneenet, J.; Monthakanitrirat, O.; Daedee, S.; Boonyarat, C.; Chotritthirong, Y.; Kwankhao, P.; Pitiporn, S.; Awale, S.; Chulikhit, Y. Merging the Multi-Target Effects of Klee Bua Daeng, a Thai Traditional Herbal Formula in Unpredictable Chronic Mild Stress-Induced Depression. Pharmaceuticals 2021, 14, 659. [CrossRef] [PubMed]

310. Friedland, K.; Silani, G.; Schuwalow, A.; Stockburger, C.; Koch, E.; Nöldner, M.; Müller, W.E. Neurotrophic Properties of Silexan, an Essential Oil from the Flowers of Lavender-Preclinical Evidence for Antidepressant-Like Properties. Pharmacopsychiatry 2021, 54, 37–46. [CrossRef]

311. Yan, T.; Wang, N.; Liu, B.; Wu, B.; Xiao, F.; He, B.; Jia, Y. Schisandra chinensis ameliorates depressive-like behaviors by regulating microbiota-gut-brain axis via its anti-inflammation activity. Phytother. Res. 2021, 35, 289–296. [CrossRef]

312. Zhang, Y.-X.; Zhang, X.-T.; Li, H.-J.; Zhou, T.-F.; Zhou, A.-C.; Zhong, Z.-L.; Liu, Y.-H.; Yuan, L.-Z.; Zhu, H.-Y.; Luan, D.; et al. Antidepressant-like effects of helicid on a chronic unpredictable mild stress-induced depression rat model: Inhibiting the IKK/IKBα/NF-κB pathway through NCALD to reduce inflammation. Int. Immunopharmacol. 2021, 93, 107165. [CrossRef]

313. Zhao, Y.; Sun, X.; Zhang, T.; Liu, S.; Cai, E.; Zhu, H. Study on the antidepressant effect of panaxynol through the IκBα/NF-κB signaling pathway to inhibit the excessive activation of BC2 microglia. Biomed. Pharmacother. 2021, 138, 111387. [CrossRef]

314. Chen, H.; Ma, Y.; Chen, M.; Chen, J.; Chen, J. Safflower extract improves depression in mice by inhibiting the TLR4-NLRP3 inflammation-signaling pathway. Ann. Palliat. Med. 2021, 10, 8015–8023. [CrossRef]

315. Yang, J.S.; Chen, Y.W.; Feng, X.Z.; Yu, D.Q.; Liang, X.T. Chemical constituents of Armillaria mellea mycelium. I. Isolation and characterization of armillarin and armillaridin. Planta Med. 1984, 50, 288–290. [CrossRef]

316. Lin, Y.-E.; Wang, H.-L.; Lu, K.-H.; Huang, Y.-J.; Pan, Y.; Liu, W.-T.; Yang, S.-H.; Chen, M.-H.; Lu, Y.-S.; Sheen, L.-Y. Water extract of Armillaria mellea (Vahl) P. Kumm. Alleviates the depression-like behaviors in acute- and chronic mild stress-induced rodent models via anti-inflammatory action. J. Ethnopharmacol. 2021, 265, 113395. [CrossRef] [PubMed]

317. Zhou, Y.; Yan, M.; Pan, R.; Wang, Z.; Tao, X.; Li, C.; Xia, T.; Liu, X.; Chang, Q. Radix Polygalae extract exerts antidepressant effects in behavioral despair mice and chronic restraint stress-induced rats probably by promoting autophagy and inhibiting neuroinflammation. J. Ethnopharmacol. 2021, 265, 113317. [CrossRef] [PubMed]

318. Fan, L.; Peng, Y.; Wang, J.; Ma, P.; Zhao, L.; Li, X. Total glycosides from stems of Cistanche tubulosa alleviate depression-like behaviors: Bidirectional interaction of the phytochemicals and gut microbiota. Phytomedicine 2021, 83, 153471. [CrossRef] [PubMed]
319. Zhang, M.; Li, A.; Yang, Q.; Li, J.; Wang, L.; Liu, X.; Huang, Y.; Liu, L. Beneficial Effect of Alkaloids from Sophora alopecuroides on CUMS-Induced Depression Model Mice via Modulating Gut Microbiota. Front. Cell. Infect. Microbiol. 2021, 11, 665159. [CrossRef]

320. Wang, X.-Q.; Tang, Y.-H.; Zeng, G.-R.; Wu, L.-F.; Zhou, Y.-J.; Cheng, Z.-N.; Jiang, D.-J. Carnosic acid alleviates depression-like behaviors on chronic mild stressed mice via PPAR-y-dependent regulation of ADPN/FGF9 pathway. Psychopharmacology 2021, 238, 501–516. [CrossRef]

321. Liu, P.; Du, J. Oridonin is an antidepressant molecule working through the PPAR-γ/AMPA receptor signaling pathway. Biochim. Pharmacol. 2020, 180, 114136. [CrossRef]

322. Zimath, P.L.; Dalmagro, A.P.; Mota da Silva, L.; Malheiro, A.; Maria de Souza, M. Myrsinoic acid B from Myrsine coriacea reverses depression-like behavior and brain oxidative stress in streptozotocin-diabetic rats. Chem. Biol. Interact. 2021, 347, 109603. [CrossRef]

323. Es-Safi, I.; Mechchate, H.; Amaghnouje, A.; Kamaly, O.M.A.; Jawhari, F.Z.; Imtara, H.; Grafov, A.; Bousta, D. The Potential of Parsley Polyphenols and Their Antioxidant Capacity to Help in the Treatment of Depression and Anxiety: An In Vivo Subacute Study. Molecules 2021, 26, 2009. [CrossRef]

324. Zimath, P.L.; Dalmagro, A.P.; Mota da Silva, L.; Malheiro, A.; Maria de Souza, M. Myrsinoic acid B from Myrsine coriacea reverses depression-like behavior and brain oxidative stress in streptozotocin-diabetic rats. Chem. Biol. Interact. 2021, 347, 109603. [CrossRef]

325. Es-Safi, I.; Mechchate, H.; Amaghnouje, A.; Kamaly, O.M.A.; Jawhari, F.Z.; Imtara, H.; Grafov, A.; Bousta, D. The Potential of Parsley Polyphenols and Their Antioxidant Capacity to Help in the Treatment of Depression and Anxiety: An In Vivo Subacute Study. Molecules 2021, 26, 2009. [CrossRef]

326. Brimson, J.M.; Brimson, S.; Prasanth, M.I.; Thitilertdecha, P.; Malar, D.S.; Tencomnao, T. The effectiveness of Bacopa monnieri in reducing cognitive decline and depressive behaviors on chronic mild stressed mice via PPAR-y-dependent regulation of ADPN/FGF9 pathway. Psychopharmacology 2021, 238, 501–516. [CrossRef]

327. Mallik, I.; Es-Safi, I.; El Moussaoui, A.; Mechchate, H.; El Majdoub, Y.O.; Bouymajane, A.; Cacciola, E.; Mondello, L.; Elbadouai, K. Salvia officinalis and Lippia triphylla: Chemical characterization and evaluation of antidepressant-like activity. J. Pharm. Biomed. Anal. 2021, 203, 114207. [CrossRef] [PubMed]

328. Perez, S.; Khan, H.; Pervaiz, A. Plant Alkaloids as an Emerging Therapeutic Alternative for the Treatment of Depression. Front. Pharmacol. 2016, 7, 28. [CrossRef] [PubMed]

329. Zhou, N.; Gu, X.; Zhuang, T.; Xu, Y.; Yang, L.; Zhou, M. Gut Microbiota: A Pivotal Hub for Polyphenols as Antidepressants. Trends Food Sci. Technol. 2016, 143, 106337. [CrossRef] [PubMed]

330. Perica, M.M.; Delaš, I. Essential Fatty Acids and Psychiatric Disorders. Nutr. Clin. Pract. 2011, 26, 409–425. [CrossRef] [PubMed]

331. Song, C.; Shieh, C.-H.; Wu, Y.-S.; Kalueff, A.; Gaikwad, S.; Su, K.-P. The role of omega-3 polyunsaturated fatty acids eicosapentaenoic and docosahexaenoic acids in the treatment of major depression and Alzheimer’s disease: Acting separately or synergistically? Prog. Lipid Res. 2016, 62, 41–54. [CrossRef]

332. Watkins, B.A.; Kim, J. The endocannabinoid system: Directing eating behavior and macronutrient metabolism. Front. Psychol. 2014, 5, 1506. [CrossRef]

333. Watson, J.E.; Kim, J.S.; Das, A. Emerging class of omega-3 fatty acid endocannabinoids & their derivatives. Prostaglandins Other Lipid Mediat. 2019, 143, 106337. [CrossRef]

334. Hibel, J.R.; Ferguson, T.A.; Blasbalg, T.L. Omega-3 fatty acid deficiencies in neurodevelopment, aggression and autonomic dysregulation: Opportunities for intervention. Int. Rev. Psychiatry 2006, 18, 107–118. [CrossRef]

335. Haberka, M.; Mizia-Stec, K.; Mizia, M.; Gieszczyk, K.; Chmiel, A.; Sitińsk-Warchulska, K.; Gasior, Z. Effects of n-3 polyunsaturated fatty acids on depressive symptoms, anxiety and emotional state in patients with acute myocardial infarction. Pharmacol. Rep. 2013, 65, 59–68. [CrossRef] [PubMed]

336. Bae, J.-H.; Kim, G. Systematic review and meta-analysis of omega-3-fatty acids in elderly patients with depression. Nutr. Res. 2018, 50, 1–9. [CrossRef] [PubMed]

337. Jiang, W.; Whellan, D.J.; Adams, K.F.; Babyak, M.A.; Boyle, S.H.; Wilson, J.L.; Patel, C.B.; Rogers, J.G.; Harris, W.S.; O’Connor, C.M. Long-Chain Omega-3 Fatty Acid Supplements in Depressed Heart Failure Patients: Results of the OCEAN Trial. JACC: Heart Fail. 2018, 6, 833–843. [CrossRef]

338. Luo, X.-D.; Feng, J.-S.; Yang, Z.; Huang, Q.-T.; Lin, J.-D.; Yang, B.; Su, K.-P.; Pan, J.-Y. High-dose omega-3 polyunsaturated fatty acid supplementation might be more low-dose for major depressive disorder in early therapy period: A network meta-analysis. BMC Psychiatry 2020, 20, 248. [CrossRef] [PubMed]

339. Khajehnasiri, F.; Akhondzadeh, S.; Mortazavi, S.B.; Allameh, A.; Sotoudeh, G.; Khavanin, A.; Zamanian, Z. Are Supplementation of Omega-3 and Ascorbic Acid Effective in Reducing Oxidative Stress and Depression among Depressed Shift Workers? Int. J. Vitam. Nutr. Res. 2016, 10, 1–12. [CrossRef] [PubMed]

340. Jahangard, L.; Sadeghi, A.; Ahmadpanah, M.; Holsooer-Trachser, E.; Sadeghi Bahmani, D.; Haghhighi, M.; Brand, S. Influence of adjuvant omega-3-polyunsaturated fatty acids on depression, sleep, and emotion regulation among outpatients with major depressive disorders. J. Psychiatr. Res. 2018, 107, 48–56. [CrossRef]

341. Newberry, S.; Hempel, S.; Booth, M.; Ewing, B.; Maher, A.R.; O’Hanlon, C.E.; Sloan, J.; Vaughan, C.A.; Dudley, W.; Shamman, R.M. Omega-3 Fatty Acids for Major Depressive Disorder: A Systematic Review. National Defense Research Institute: Santa Monica, CA, USA, 2015.
342. Hallahan, B.; Ryan, T.; Hibbeln, J.R.; Murray, I.T.; Glynn, S.; Ramsden, C.E.; SanGiovanni, J.P.; Davis, J.M. Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression. *Br. J. Psychiatry* 2016, 209, 192–201. [CrossRef]

343. Liao, Y.; Xie, B.; Zhang, H.; He, Q.; Guo, L.; Subramaniampillai, M.; Fan, B.; Lu, C.; McIntyre, R.S. Efficacy of omega-3 PUFAs in depression: A meta-analysis. *Transl. Psychiatry* 2019, 9, 190. [CrossRef]

344. Mischoulon, D.; Nierenberg, A.A.; Schettler, P.J.; Kinkead, B.L.; Fehling, K.; Martinson, M.A.; Hyman Rapaport, M. A double-blind, randomized controlled clinical trial comparing eicosapentaenoic acid versus docosahexaenoic acid for depression. *J. Clin. Psychiatry* 2015, 76, 54–61. [CrossRef]

345. Shinto, L.; Marracci, G.; Mohr, D.C.; Bumgarner, L.; Murchison, C.; Senders, A.; Bourdette, D. Omega-3 Fatty Acids for Depression in Multiple Sclerosis: A Randomized Pilot Study. *PLoS ONE* 2016, 11, e0147195. [CrossRef]

346. Gabbay, V.; Freed, R.D.; Alonso, C.M.; Senger, S.; Stadterman, J.; Davison, B.A.; Klein, R.G. A Double-Blind Placebo-Controlled Trial of Omega-3 Fatty Acids as a Monotherapy for Adolescent Depression. *J. Clin. Psychiatry* 2018, 79, 17m11596. [CrossRef]

347. Mazereeuw, G.; Herrmann, N.; Oh, P.I.; Ma, D.W.; Wang, C.T.; Kiss, A.; Lancot, K.L. Omega-3 Fatty Acids, Depressive Symptoms, and Cognitive Performance in Patients with Coronary Artery Disease: Analyses from a Randomized, Double-Blind, Placebo-Controlled Trial. *J. Clin. Psychopharmacol.* 2016, 36, 436–444. [CrossRef] [PubMed]

348. Carney, R.M.; Freedland, K.E.; Rubin, E.H.; Rich, M.W.; Steinmeyer, B.C.; Harris, W.S. A Randomized Placebo-Controlled Trial of Omega-3 and Sertraline in Depressed Patients with or at Risk for Coronary Heart Disease. *J. Clin. Psychiatry* 2019, 80, 19m12742. [CrossRef]

349. Zhang, L.; Liu, H.; Kuang, L.; Meng, H.; Zhou, X. Omega-3 fatty acids for the treatment of depressive disorders in children and adolescents: A meta-analysis of randomized placebo-controlled trials. *Child Adolesc. Psychiatry Ment. Health* 2019, 13, 36. [CrossRef]

350. Bai, Z.-G.; Bo, A.; Wu, S.-J.; Gai, Q.-Y.; Chi, I. Omega-3 polyunsaturated fatty acids and reduction of depressive symptoms in older adults: A systematic review and meta-analysis. *J. Affect. Disord.* 2018, 241, 241–248. [CrossRef] [PubMed]

351. Deyama, S.; Ishikawa, Y.; Yoshikawa, K.; Shimoda, K.; Ide, S.; Satoh, M.; Minami, M. Resolvin E1/E2 ameliorate lipopolysaccharide-induced depression-like behaviors via ChemR23. *Psychopharmacology* 2018, 235, 329–336. [CrossRef] [PubMed]

352. Deyama, S.; Shimoda, K.; Suzuki, H.; Ishikawa, Y.; Ishimura, K.; Fukuda, H.; Hitotra-Imamura, N.; Ide, S.; Satoh, M.; Kaneda, K.; et al. Resolvin E1/E2 ameliorate lipopolysaccharide-induced depression-like behaviors via ChemR23. *Psychopharmacology* 2018, 235, 329–336. [CrossRef] [PubMed]

353. Deyama, S.; Shimoda, K.; Ikeda, H.; Fukuda, H.; Shuto, S.; Minami, M. Resolvin E3 attenuates lipopolysaccharide-induced depression-like behavior in mice. *J. Pharmacol. Sci.* 2018, 138, 86–88. [CrossRef] [PubMed]